呼吸器診療　ANDS BOOK

出版社： 中外医学社
著者：
発行日： 2019-09-20
分野： 臨床医学：内科  >  呼吸器一般
ISBN： 9784498130449
電子書籍版： 2019-09-20 （初版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,920 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,920 円(税込)

購入する

商品紹介

杏林大学呼吸器内科のスタッフが現時点での総力を結集して作り上げた骨太の診療エッセンス＆パールズ。呼吸器診療という名の大海を泳ぎ切るための診断政略、見逃してはならない疾患を確実に掬い上げるためのポイント、普遍的でありながらも重要な身体所見・バイタルのとりかた、診療に役立つ検査所見の知識、初級編から上級編まで縦横に網羅された珠玉のパールズなど、呼吸器診療に携わるすべての医師の臨床力をワンランク引き上げる充実の内容。

目次

  • 第1章　診断戦略
    　1　呼吸器診療の大海を泳ぐ

    第2章　症状/主要徴候
    　1　見逃してはならない疾患を想起する
    　2　血痰・喀血
    　3　胸痛
    　4　咳嗽：多彩な疾患群を捉える

    第3章　身体所見とバイタルサイン
    　1　バイタルサイン総論：時代を経ても変わらない大事なもの
    　2　視診
    　3　触診
    　4　打診
    　5　聴診
    　6　一般内科医/呼吸器内科医のための心疾患の診かた

    第4章　検査所見を診療に生かす
    　1　病理診断に強くなる
    　2　バイオマーカーに強くなる
    　3　画像診断に強くなる：１　胸部X線
    　4　画像診断に強くなる：２　胸部CT
    　5　画像診断に強くなる：３　肺エコー

    第5章　ANDSパールズ：初級編（Basic）
    　1　知っておきたい酸素の極意
    　2　薬のオキテ/ミニマムエッセンス
    　3　マクロライド千思万考
    　4　吸入薬：デバイスの違いを理解する
    　5　肺炎：木を見て森を見ず，にならないために…
    　6　呼吸器ウイルス感染症
    　7　肺結核総論
    　8　肺結核各論
    　9　非定型抗酸菌症
    　10　間質性肺炎
    　11　気胸：bulla，blebは大畑分類を理解する
    　12　呼吸器と膠原病肺
    　13　咳嗽：そのオキテ
    　14　喘息
    　15　COPD：まずは診断
    　16　COPD：評価と治療
    　17　発癌リスク
    　18　癌と転移

    第6章　ANDSパールズ：中級編（Standard）
    　1　検査と身体所見：特別編
    　2　肺胞出血：ヘモジデリンを活用せよ
    　3　アスペルギルス：まさにカメレオン
    　4　いつか出会う合併症
    　5　呼吸器病と妊娠
    　6　緩和ケア：疼痛コントロールの実際
    　7　介護と福祉：多職種によるチームプレー

    第7章　ANDSパールズ：上級編（Advanced）
    　1　肺炎一般/アレルギー
    　2　間質性肺炎
    　3　膿胸/胸水
    　4　肺癌の治療戦略
    　5　特殊な間質性肺炎と吸入抗原による肺/胸膜疾患
    　6　治療のトピック

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 診断戦略

P.6 掲載の参考文献
(1) Cunha BA. The master clinician's approach to diagnostic reasoning. Am J Med. 2017 ; 130 : 5-7.
PubMed

第2章 症状 / 主要徴候

P.9 掲載の参考文献
(1) Manning HL, et al. Pathophysiology of dyspnea. N Engl J Med. 1995 ; 333 : 1547-53.
PubMed
(2) Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.com
 
(3) Miyamoto K. Confusion about MRC dyspnea scales in Japan--which MRC dyspnea scale should we employ? Nihon Kokyuki Gakkai Zasshi. 2008 ; 46 : 593-600.
PubMed
P.15 掲載の参考文献
(1) Jain S, et al. Community-acquired pneumonia requiring hospitalization among U.S. Adults. N Engl J Med. 2015 ; 373 : 415-27.
PubMed
(2) Nagatomo T, et al. Two cases of bilateral bronchial artery varices : one with and one without bilateral coronary-to-pulmonary artery fistulas. Review and characterization of the clinical features of bronchial artery varices reported in Japan. Clin Radiol. 2012 ; 67 : 1212-7.
PubMed
(3) Nagatomo T, et al. Re : Two cases of bilateral bronchial artery varices : one with and one without bilateral coronary-to-pulmonary artery fistulas. Review and characterization of the clinical features of bronchial artery varices reported in Japan. A reply. Clin Radiol. 2013 ; 68 : 750
PubMed
P.18 掲載の参考文献
(1) Metlay JP, et al. Influence of age on symptoms at presentation in patients with communityacquired pneumonia. Arch Intern Med. 1997 ; 157 : 1453-9.
PubMed
P.20 掲載の参考文献
(1) 上地嚢. 胸痛診療のポイント. 中部病院医誌. 1986 ; 12 : 4-9.
 
(2) Saraya T, et al. Diagnostic value of vascular endothelial growth factor, transforming growth factor-β, interleukin-8, and the ratio of lactate dehydrogenase to adenosine deaminase in pleural effusion. Lung. 2018 ; 196 : 249-54.
 
(3) Douma RA, et al. Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism : a prospective cohort study. Ann Intern Med. 2011 ; 154 : 709-18.
PubMed
P.24 掲載の参考文献
(1) Hanak V, et al. Cough-induced rib fractures. Mayo Clin Proc. 2005 ; 80 : 879-82.
PubMed
P.25 掲載の参考文献
(1) Chung KF, et al. Prevalence, pathogenesis, and causes of chronic cough. Lancet. 2008 ; 371 : 1364-74.
PubMed
(2) Nishizawa T, et al. Good syndrome occurred in a patient a prolonged time after thymectomy : a case report and literature review of cases in Japan. J Gen Fam Med. 2016 ; 17 : 238-43.
 
(3) van Manen MJ, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016 ; 25 : 278-86.
PubMed
(4) Key AL, et al. Objective cough frequency in idiopathic pulmonary fibrosis. Cough. 2010 ; 6 : 4.
PubMed
(5) Currie GP, et al. Chronic cough. BMJ. 2003 ; 326 : 261.
PubMed
(6) Damaraju D, et al. Clinical problem-solving. A surprising cause of chronic cough. N Engl J Med. 2015 ; 373 : 561-6.
PubMed
(7) Grenier PA, et al. Nonneoplastic tracheal and bronchial stenoses. Radiol Clin North Am. 2009 ; 47 : 243-60.
PubMed
(8) Saraya T, et al. Critical pitfall : arther cause of wheezing BMJ Case Rep. 2017. doi : 10.1136/bcr-2017-223147.
 

第3章 身体所見とバイタルサイン

P.31 掲載の参考文献
(1) Verghese A. 2011. https://www.ted.com/talks/abraham_verghese_a_doctor_s_touch?language=ja
 
(2) Cunha BA. The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol Infect. 2000 ; 6 : 633-4.
PubMed
(3) Commission on respiratory diseases. The transmission of primary atypical pneumonia to human volunteers ; experimental methods. Bull Johns Hopkins Hosp. 1946 ; 79 : 97-108.
PubMed
(4) Saraya T, et al. Correlation between clinical features, high-resolution computed tomography findings, and a visual scoring system in patients with pneumonia due to Mycoplasma pneumoniae. Respir Investig. 2018 ; 56 : 320-5.
 
(5) Ostergaard L, et al. Relative bradycardia in infectious diseases. J Infect. 1996 ; 33 : 185-91.
PubMed
(6) Simon HB. Extreme pyrexia. JAMA. 1976 ; 236 : 2419-21.
PubMed
(7) Mackowiak PA, et al. Drug fever : a critical appraisal of conventional concepts. An analysis of 51 episodes in two Dallas hospitals and 97 episodes reported in the English literature. Ann Intern Med. 1987 ; 106 : 728-33.
 
(8) Tokuda Y, et al. The degree of chills for risk of bacteremia in acute febrile illness. Am J Med. 2005 ; 118 : 1417.
PubMed
(9) Watari T, et al. Bleeding from a gut lesion as a cause of seizure. BMJ Case Rep. 2015 ; 2015. pii : bcr2014205619.
 
(10) McGee S. Evidence-based physical diagnosis. 2nd ed. Saunders ; 2007.
 
(11) Srygley FD, et al. Does this patient have a severe upper gastrointestinal bleed? JAMA. 2012 ; 307 : 1072-9.
PubMed
P.43 掲載の参考文献
(1) Souza EJ, et al. Nailfold capillaroscopy : relevance to the practice of rheumatology. Rev Bras Reumatol. 2015 ; 55 : 264-71.
 
P.47 掲載の参考文献
(1) Schwartz RA, et al. Erythema nodosum : a sign of systemic disease. Am Fam Physician. 2007 ; 75 : 695-700.
PubMed
P.53 掲載の参考文献
(1) Roujeau JC, et al. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994 ; 331 : 1272-85.
PubMed
(2) Stern RS. Clinical practice. Exanthematous drug eruptions. N Engl J Med. 2012 ; 366 : 2492-501.
PubMed
(3) Bocquet H, et al. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms : DRESS). Semin Cutan Med Surg. 1996 ; 15 : 250-7.
PubMed
(4) Vittorio CC, et al. Anticonvulsant hypersensitivity syndrome. Arch Intern Med. 1995 ; 155 : 2285-90.
PubMed
(5) Akashi K, et al. Brief report : severe infectious mononucleosis-like syndrome and primary human herpesvirus 6 infection in an adult. N Engl J Med. 1993 ; 329 : 168-71.
 
(6) Saraya T, et al. Evidence for reactivation of human herpesvirus 6 in generalized lymphadenopathy in a patient with drug-induced hypersensitivity syndrome. J Clin Microbiol. 2013 ; 51 : 1979-82.
 
P.57 掲載の参考文献
(1) Wilson LD, et al. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007 ; 356 : 1862-9.
PubMed
(2) Bruno TF, et al. Superior vena cava syndrome and telangiectasia in a man with lymphoma. CMAJ. 2007 ; 177 : 1177-9.
 
P.59 掲載の参考文献
(1) Saraya T, et al. Reversed halo sign caused by huge tricuspid native valve infective endocarditis associated with community-acquired methicillin-resistant Staphylococcus aureus. JMM Case Reports. 2015 ; 2.
 
(2) Macklem PT. Respiratory muscle dysfunction. Hosp Pract (Off Ed). 1986 ; 21 : 83-90, 95-6.
 
(3) Saraya T, et al. Paradoxical respiration : "Seesaw" motion with massive pulmonary consolidation. BMJ Case Rep. 2016. doi : 10.1136/bcr-2015-213449.
 
(4) Nakajima A, et al. The saw-tooth sign as a clinical clue for intrathoracic central airway obstruction. BMC Res Notes. 2012 ; 5 : 388.
PubMed
(5) Jane M, 著. 須藤博, 他訳. 全身状態. サパイラ 身体診察のアートとサイエンス. 原著第4版. 東京 : 医学書院 ; 2013. p.127-34.
 
(6) Takase B, et al. Importance of platypnea orthodeoxia in the differential diagnosis of dyspnea. Intern Med. 2012 ; 51 : 1651-2.
PubMed
(7) Ioachimescu OC, et al. A middle-aged woman with chronic liver disease and shortness of breath. Cleve Clin J Med. 2006 ; 73 : 375-81.
PubMed
(8) Rodriguez-Roisin R, et al. Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med. 2008 ; 358 : 2378-87.
PubMed
(9) Rebick G, et al. The thinker's sign. CMAJ. 2008 ; 179 : 611.
PubMed
(10) Frankel SK, et al. Idiopathic pleuroparenchymal fibroelastosis : description of a novel clinicopathologic entity. Chest. 2004 ; 126 : 2007-13.
PubMed
(11) Tokuda Y, et al. Physical diagnosis of chronic obstructive pulmonary disease. Intern Med. 2007 ; 46 : 1885-91.
PubMed
(12) Tsujimoto N, et al. Flapping tremor as a diagnostic tool for evaluation of hypercapnia. Pulm Res Respir Med Open J. 2015 ; 2 : 49-51.
 
(13) Fawcett RS, et al. Nail abnormalities : clues to systemic disease. Am Fam Physician. 2004 ; 69 : 1417-24.
PubMed
(14) Saraya T, et al. Non-syndromic brachydactyly, known as Shamoji-yubi or Mamushi-yubi in Japan. BMJ Case Rep. 2013 ; 2013. pii : bcr2013201242.
PubMed
(15) Souza EJ, et al. Nailfold capillaroscopy : relevance to the practice of rheumatology. Rev Bras Reumatol. 2015 ; 55 : 264-71.
 
(16) Saraya T, et al. Terry's nails as a part of aging. Intern Med. 2008 ; 47 : 567-8.
 
(17) Saraya T, et al. Yellow nail syndrome in toenails. Intern Med. 2015 ; 54 : 2089.
PubMed
(18) Pallares-Sanmartin A, et al. Validity and reliability of the Schamroth sign for the diagnosis of clubbing. JAMA. 2010 ; 304 : 159-61.
PubMed
(19) Sohara E, et al. Mechanic's hands revisited : is this sign still useful for diagnosis in patients with lung involvement of collagen vascular diseases? BMC Res Notes. 2014 ; 7 : 303.
 
(20) Goundry B, et al. Diagnosis and management of Raynaud's phenomenon. BMJ. 2012 ; 344 : e289.
PubMed
(21) Wigley FM, et al. Raynaud's Phenomenon. N Engl J Med. 2016 ; 375 : 556-65.
PubMed
(22) Kurzrock R, et al. Cutaneous paraneoplastic syndromes in solid tumors. Am J Med. 1995 ; 99 : 662-71.
PubMed
(23) Schneider LC, et al. Diagnosis of oral ulcers. Mt Sinai J Med. 1998 ; 65 : 383-7.
PubMed
(24) McBride DR. Management of aphthous ulcers. Am Fam Physician. 2000 ; 62 : 149-54, 160.
PubMed
(25) Scully C, et al. ABC of oral health. Mouth ulcers and other causes of orofacial soreness and pain. BMJ. 2000 ; 321 : 162-5.
PubMed
(26) Saraya T, et al. Not paraneoplastic pemphigus but pemphigus vulgaris in a patient with thymoma. BMJ Case Rep. 2015 ; 2015. pii : bcr2015210433.
 
(27) Ahmed AR, et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 23-2003. A 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. N Engl J Med. 2003 ; 349 : 382-91.
PubMed
(28) Kardaun SH, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms : does a DRESS syndrome really exist? Br J Dermatol. 2007 ; 156 : 609-11.
PubMed
(29) Bocquet H, et al. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms : DRESS). Semin Cutan Med Surg. 1996 ; 15 : 250-7.
PubMed
(30) Ushigome Y, et al. Human herpesvirus 6 reactivation in drug-induced hypersensitivity syndrome and DRESS validation score. Am J Med. 2012 ; 125 : e9-10.
PubMed
(31) Sidoroff A, et al. Acute generalized exanthematous pustulosis (AGEP) -a clinical reaction pattern. J Cutan Pathol. 2001 ; 28 : 113-9.
PubMed
(32) Stanford W, et al. Superior vena cava obstruction : a venographic classification. AJR Am J Roentgenol. 1987 ; 148 : 259-62.
PubMed
(33) Bashist B, et al. Abdominal CT findings when the superior vena cava, brachiocephalic vein, or subclavian vein is obstructed. AJR Am J Roentgenol. 1996 ; 167 : 1457-63.
PubMed
(34) Cihangiroglu M, et al. Collateral pathways in superior vena caval obstruction as seen on CT. J Comput Assist Tomogr. 2001 ; 25 : 1-8.
 
(35) Saraya T, et al. Huge mediastinal mass with SVC syndrome accompanying numerous chest wall collateral vessels. Intern Med. 2008 ; 47 : 1719-22.
PubMed
(36) Campbell EJ. Physical signs of diffuse airways obstruction and lung distension. Thorax. 1969 ; 24 : 1-3.
PubMed
(37) Matsuba K, et al. The number and dimensions of small airways in nonemphysematous lungs. Am Rev Respir Dis. 1971 ; 104 : 516-24.
PubMed
P.68 掲載の参考文献
(1) Bazemore AW, et al. Lymphadenopathy and malignancy. Am Fam Physician. 2002 ; 66 : 2103-10.
PubMed
(2) Ferrer R. Lymphadenopathy : differential diagnosis and evaluation. Am Fam Physician. 1998 ; 58 : 1313-20.
PubMed
(3) Nakamura I, et al. Medical study of 69 cases diagnosed as Kikuchi's disease. Kansenshogaku Zasshi. 2009 ; 83 : 363-8.
PubMed
(4) Pangalis GA, et al. Clinical approach to lymphadenopathy. Semin Oncol. 1993 ; 20 : 570-82.
PubMed
(5) Saraya T, et al. Hodgkin lymphoma with rapidly destructive, cavity-forming lung disease. J Clin Oncol. 2013 ; 31 : e211-4.
PubMed
(6) Higaki M, et al. Evidence for hypohydrosis as clinical clue to diagnosis of Horner's syndrome. BMJ Case Rep. 2013 ; 2013. pii : bcr2013009732.
 
(7) Henry JA, et al. Assessment of hypoproteinaemic oedema : a simple physical sign. Br Med J. 1978 ; 1 : 890-1.
PubMed
P.70 掲載の参考文献
(1) Honda K, et al. Tumor lysis syndrome and acquired ichthyosis occurring after chemotherapy for lung adenocarcinoma. J Clin Oncol. 2011 ; 29 : e859-60.
PubMed
P.73 掲載の参考文献
(1) Tomos I, et al. Celebrating two centuries from the invention of the stethoscope : Rene Theophile Hyacinthe Laennec (1781-1826). Ann Am Thorac Soc. 2016 ; 13 : 1667-70.
PubMed
(2) Sakula A. R T H Laennec 1781-1826 his life and work : a bicentenary appreciation. Thorax. 1981 ; 36 : 81-90.
 
(3) Sarkar M, et al. Auscultation of the respiratory system. Ann Thorac Med. 2015 ; 10 : 158-68.
PubMed
(4) Robertson AJ, et al. Rales, rhonchi, and Laennec. Lancet. 1957 ; 273 : 417-23.
PubMed
P.81 掲載の参考文献
(1) Jaiganesh T, et al. Mobile diagnosis : Hamman's crunch in a primary spontaneous pneumothorax. Emerg Med J. 2010 ; 27 : 482-3.
 
P.84 掲載の参考文献
(1) Proctor DF. All that wheezes. Am Rev Respir Dis. 1983 ; 127 : 261-2.
PubMed
(1) Loudon R, et al. Lung sounds. Am Rev Respir Dis. 1984 ; 130 : 663-73.
PubMed
(2) Nakajima A, et al. The saw-tooth sign as a clinical clue for intrathoracic central airway obstruction. BMC Res Notes. 2012 ; 5 : 388.
PubMed
(2) Pasterkamp H, et al. Respiratory sounds. Advances beyond the stethoscope. Am J Respir Crit Care Med. 1997 ; 156 : 974-87.
PubMed
(3) エイブラハム・バルギーズ. 医師の手が持つ力. https://www.ted.com/talks/abraham_verghese_a_doctor_s_touch?language=ja.
 
(4) Kudo S. 肺音研究の進歩. 日本医事新報. 1986 ; 3247 : 3-9.
 
(5) Mikami R, et al. 肺の聴診に関する国際シンポジウム. 日医師会誌. 1985 ; 94 : 2049-69.
 
(6) Mikami R, et al. International Symposium on Lung Sounds. Synopsis of proceedings. Chest. 1987 ; 92 : 342-5.
PubMed
(7) Forgacs P. Crackles and wheezes. Lancet. 1967 ; 2 : 203-5.
PubMed
(8) Earis JE, et al. The inspiratory "squawk" in extrinsic allergic alveolitis and other pulmonary fibroses. Thorax. 1982 ; 37 : 923-6.
PubMed
(9) Piirila P, et al. Crackles in patients with fibrosing alveolitis, bronchiectasis, COPD, and heart failure. Chest. 1991 ; 99 : 1076-83.
PubMed
(10) Nath AR, et al. Inspiratory crackles and mechanical events of breathing. Thorax. 1974 ; 29 : 695-8.
PubMed
(11) Miyagi S. ラ音の表現方法とその病態生理学的意義. 日本医事新報. 1992 ; 3550 : 140-1.
 
(12) Piirila P. Changes in crackle characteristics during the clinical course of pneumonia. Chest. 1992 ; 102 : 176-83.
PubMed
P.99 掲載の参考文献
(1) Wang CS, et al. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005 ; 294 : 1944-56.
PubMed
(1) Cohen M, et al. Resolution of pleural effusions. Chest. 2001 ; 119 : 1547-62.
PubMed
(2) Harle T. Congestive heart failure. In : Freundlich IM, et al. A radiologic approach to diseases of the chest. Williams & Wilkins ; 1997. p.345-59.
 
(2) 佐藤徹. 肺循環障害の日常診察で気をつけること (特集 呼吸器内科に必要な診察術). 呼吸器内科. 2016 ; 30 : 315-9.
 
(3) 室生卓. 循環器診察力腕試し. 京都 : 金芳堂 ; 2012.
 
(4) Davison R, et al. Estimation of central venous pressure by examination of jugular veins. Am Heart J. 1974 ; 87 : 279-82.
PubMed
(5) Saraya T, et al. Elevated jugular venous pressure with Y-Dip on inspection. Pulm Res Respir Med Open J. 2016 ; SE : S1-S2.
 
(6) Mansoor AM, et al. Images in clinical medicine. Kussmaul's sign. N Engl J Med. 2015 ; 372 : e3.
 
(7) Roy CL, et al. Does this patient with a pericardial effusion have cardiac tamponade? JAMA. 2007 ; 297 : 1810-8.
PubMed
(8) Saraya T, et al. The role of vital signs in predicting cardiac tamponade in asymptomatic patients with malignancy-associated pericardial effusion. Pulm Res Respir Med Open J. 2016 ; SE : S3-7.
 
(9) Takata S, et al. 悪性腫瘍に合併した心タンポナーデのvital signを含めた臨床的検討. 日呼吸会誌. 2012 ; 1 : 182.
 
(10) Saraya T, et al. Utility of a sticky note "Post-it" and a cotton swab as a tool to aid cardiac examination. Pulm Res Respir Med Open J. 2016 ; SE : S17-19.
 

第4章 検査所見を診療に生かす

P.109 掲載の参考文献
(1) Shimoda M, et al. A significance of bacterial engulfment in patients with respiratory infections. Medicine (Baltimore). 2018 ; 97 : e0150.
 
(2) Fukuyama H, et al. Validation of sputum Gram stain for treatment of community-acquired pneumonia and healthcare-associated pneumonia : a prospective observational study. BMC Infect Dis. 2014 ; 14 : 534.
PubMed
(3) Sieger B, et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin : a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med. 1997 ; 25 : 1663-70.
PubMed
P.118 掲載の参考文献
(1) Obayashi T, et al. Plasma (1→3) -beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet. 1995 ; 345 : 17-20.
 
(2) Yoshida K. Utility of the (1→3) -β-D-glucan test in diagnosis of invasive fungal infections. Med J Kinki Univ. 2015 ; 40 : 77-81.
 
(3) Odabasi Z, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections : validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004 ; 39 : 199-205.
PubMed
(4) Ostrosky-Zeichner L, et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005 ; 41 : 654-9.
 
(5) Kedzierska A, et al. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans : galactomannan, mannan and (1→3) -beta-D-glucan antigens. Eur J Clin Microbiol Infect Dis. 2007 ; 26 : 755-66.
 
(6) Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis. 2003 ; 5 : 158-66.
PubMed
P.128 掲載の参考文献
(1) Sturgeon CM, et al. Serum tumour markers : how to order and interpret them. BMJ. 2009 ; 339 : b3527.
PubMed
(1) Becker KL, et al. Procalcitonin assay in systemic inflammation, infection, and sepsis : clinical utility and limitations. Crit Care Med. 2008 ; 36 : 941-52.
PubMed
(2) Perkins GL, et al. Serum tumor markers. Am Fam Physician. 2003 ; 68 : 1075-82.
PubMed
(2) Ghillani PP, et al. Identification and measurement of calcitonin precursors in serum of patients with malignant diseases. Cancer Res. 1989 ; 49 : 6845-51.
PubMed
(3) Wilt TJ, et al. Clinically localised prostate cancer. BMJ. 2006 ; 333 : 1102-6.
PubMed
(4) Kuno T, et al. Tumor marker in patients on chronic hemodialysis. 日臨. 2004 ; 62 : 391-4.
 
(5) Nakahama H, et al. CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients. Respirology. 1998 ; 3 : 207-10.
PubMed
(6) Cases A, et al. Tumor markers in chronic renal failure and hemodialysis patients. Nephron. 1991 ; 57 : 183-6.
PubMed
(7) Nomura F, et al. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure. Oncol Rep. 1998 ; 5 : 389-92.
PubMed
(8) Kohno N, et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989 ; 96 : 68-73.
PubMed
(9) Ohnishi H, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002 ; 165 : 378-81.
PubMed
(10) Ishii H, et al. High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Thorax. 2003 ; 58 : 52-7.
PubMed
(11) Ohnishi H, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003 ; 58 : 872-5.
PubMed
(12) Tamura M, et al. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. Oncologist. 2013 ; 18 : 454-9.
PubMed
(13) Otsuka M, et al. New serum markers to monitor treatment of acute exacerbation of interstitial lung disease. Nihon Kokyuki Gakkai Zasshi. 2001 ; 39 : 298-302.
PubMed
(14) Yokoyama A, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006 ; 11 : 164-8.
PubMed
(15) Satoh H, et al. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med. 2006 ; 260 : 429-34.
PubMed
(16) Ohshimo S, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med. 2014 ; 108 : 1031-9.
PubMed
(17) Medina L, et al. Importance of Bnp changes during the follow-up in elderly outpatients with heart failure. Clin Biochem. 2014 ; 47 : 1010-4.
PubMed
(18) Sakai A, et al. The role of tumor-associated macrophages on serum soluble IL-2R levels in B-cell lymphomas. J Clin Exp Hematop. 2014 ; 54 : 49-57.
 
(19) Bien E, et al. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children : a review. Biomarkers. 2008 ; 13 : 1-26.
PubMed
(20) Kamihira S, et al. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer. 1994 ; 73 : 2753-8.
PubMed
(21) Nishizawa T, et al. Antemortem diagnosis with multiple random skin biopsies and transbronchial lung biopsy in a patient with intravascular large B-cell lymphoma, the so-called Asian variant lymphoma. BMJ Case Rep. 2014 ; 2014 : bcr2013202661.
 
(22) 三友貴代, 他. Intravascular large B-cell lymphomaの2例-皮膚所見と生検のポイント. 臨皮. 2015 ; 69 : 761-6.
 
(23) Zuckerman D, et al. Intravascular lymphoma : the oncologist's "great imitator". Oncologist. 2006 ; 11 : 496-502.
PubMed
(24) Yoshizato T, et al. Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2013 ; 13 : 410-6.
PubMed
(25) Koide T, et al. Clinical significance of the "galaxy sign" in patients with pulmonary sarcoidosis in a Japanese single-center cohort. Sarcoidosis Vasc Diffuse Lung Dis. 2016 ; 33 : 247-52.
 
(26) 木島まゆみ. 日本で使用されている動物用診断薬 牛感染症とその診断薬の概説 結核病. 日本獣医師会誌. 2014 ; 67 : 11-2.
 
(27) 大森正子. 結核既感染者数の推計. 公益財団法人結核予防会結核研究所. 2009.
 
(28) Fujita A, et al. Performance of a whole-blood interferon-gamma release assay with Mycobacterium RD1-specific antigens among HIV-infected persons. Clin Dev Immunol. 2011 ; 2011 : 325295.
PubMed
(29) 徳永修, 他. 新しい結核感染診断法の課題と展望 小児へのQFT等の適用とその課題. 結核. 2010 ; 85 : 21-3.
 
(30) 日本結核病学会予防委員会. インターフェロンγ遊離試験使用指針. 結核. 2014 ; 89 : 717-25.
Medical*Online
(31) 加藤誠, 他. インターフェロンγ遊離試験使用指針. 結核. 2014 ; 89 : 717-25.
 
(32) Browne SK, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012 ; 367 : 725-34.
PubMed
(33) Sakagami T. Disseminated nontuberculous mycobacteriosis that is positive for neutralizing anti-interferon-gamma autoantibodies : a new disease concept based on host factors. Kekkaku. 2015 ; 90 : 561-4.
PubMed
(34) Ghillani PP, et al. Identification and measurement of calcitonin precursors in serum of patients with malignant diseases. Cancer Res. 1989 ; 49 : 6845-51.
PubMed
(35) Assicot M, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993 ; 341 : 515-8.
PubMed
(36) Muller B, et al. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001 ; 86 : 396-404.
PubMed
(37) Linscheid P, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells : a novel product of human adipose tissue. Endocrinology. 2003 ; 144 : 5578-84.
 
(38) Tamura M, et al. Serial quantification of procalcitonin (PCT) predicts clinical outcome and prognosis in patients with community-acquired pneumonia (CAP). J Infect Chemother. 2014 ; 20 : 97-103.
 
(39) Kruger S, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008 ; 31 : 349-55.
PubMed
(40) Huang DT, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med. 2008 ; 52 : 48-58, e2.
 
(41) Schuetz P, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections : the ProHOSP randomized controlled trial. JAMA. 2009 ; 302 : 1059-66.
PubMed
P.156 掲載の参考文献
(1) Saraya T, et al. Phantom tumour of the lung. BMJ Case Rep. 2013 ; 2013 : bcr2013010457.
PubMed
(2) Koga T, et al. Images in clinical medicine. Kerley's A, B, and C lines. N Engl J Med. 2009 ; 360 : 1539.
 
(3) Nagatomo T, et al. Bronchial schwannoma masquerading as cause of hemoptysis in a patient with pulmonary embolism. General Medicine. 2013 ; 14 : 67-71.
 
(4) Saraya T, et al. Broncholithiasis and lithoptysis associated with diffuse panbronchiolitis. Intern Med. 2016 ; 55 : 2315-6.
PubMed
(5) Saraya T, et al. Tracheobronchial amyloidosis in a patient with Sjogren's syndrome. Intern Med. 2016 ; 55 : 981-4.
 
(6) Ohkuma K, et al. Esophageal malignancy with an esophagorespiratory fistula masquerading as pneumonia. Intern Med. 2016 ; 55 : 2119-20.
PubMed
(7) Ohkuma K, et al. Massive barium sulfate aspiration in the bronchial tree. Intern Med. 2015 ; 54 : 2081.
PubMed
(8) Saraya T, et al. Othello pica : a clue of recurrent rectal cancer. Intern Med. 2015 ; 54 : 2525.
 
(9) Saraya T, et al. A memory of World War II in an elderly Japanese man. J Gen Fam Med. 2015 ; 16 : 305-6.
 
P.169 掲載の参考文献
(1) Hochberg EP, et al. Case records of the Massachusetts General Hospital. Case 17-2006--a 34-year-old man with cavitary lung lesions. N Engl J Med. 2006 ; 354 : 2485-93.
PubMed
(2) Mireles-Cabodevila E, et al. A young patient with a minimal smoking history presents with bullous emphysema and recurrent pneumothorax. Chest. 2007 ; 132 : 338-43.
 
P.171 掲載の参考文献
(1) Patel VK, et al. A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules : part 1 : radiologic characteristics and imaging modalities. Chest. 2013 ; 143 : 825-39.
 
(1) Ch'in KY, et al. Congenital adenomatoid malformation of one lobe of a lung with general anasarca. Arch Pathol. 1949 ; 48 : 221-9.
PubMed
(2) Stocker JT, et al. Congenital cystic adenomatoid malformation of the lung. Classification and morphologic spectrum. Hum Pathology. 1977 ; 8 : 155-71.
PubMed
(2) McNulty W, et al. Investigating the solitary pulmonary nodule. BMJ. 2012 ; 344 : e2759.
PubMed
(3) Klein JS, et al. Imaging evaluation of the solitary pulmonary nodule. Clin Chest Med. 2008 ; 29 : 15-38, v.
PubMed
(3) Edward Y, et al. Multidetector CT evaluation of congenital lung anomalies. Radiology. 2008 ; 3 : 632-48.
 
(4) 松田佳也, 他. 成人で発見されたcongenital cystic adenomatoid malformationの1例. 日呼外会誌. 2009 ; 23 : 105-9.
 
(4) Ost D, et al. Clinical practice. The solitary pulmonary nodule. N Engl J Med. 2003 ; 348 : 2535-42.
PubMed
(5) http://kompas.hosp.keio.ac.jp/contents/000131.html
 
(5) Albert RH, et al. Evaluation of the solitary pulmonary nodule. Am Fam Physician. 2009 ; 80 : 827-31.
PubMed
(6) Wahidi MM, et al. Evidence for the treatment of patients with pulmonary nodules : when is it lung cancer? : ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 ; 132 (3 Suppl) : 94S-107S.
 
(7) MacMahon H, et al. Guidelines for management of small pulmonary nodules detected on CT scans : a statement from the Fleischner Society. Radiology. 2005 ; 237 : 395-400.
 
(8) Gould MK, et al. Evaluation of patients with pulmonary nodules : when is it lung cancer? : ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 ; 132 (3 Suppl) : 108S-130S.
 
(9) Saraya T, et al. Fluorodeoxyglucose (FDG) uptake in pulmonary rheumatoid nodules diagnosed by video-assisted thoracic surgery lung biopsy : two case reports and a review of the literature. Mod Rheumatol. 2013 ; 23 : 393-6.
 
(10) Nakamoto Y, et al. PET/CTおよび胸腔鏡下肺生検による組織学的評価を施行し得た肺リウマチ結節の1例. 日胸. 2014 ; 73 : 1472-7.
 
(11) Saraya T. Pulmonary aspergillosis mimicking primary lung cancer. Pulm Res Respir Med Open J. 2015 ; 2 : 75-6.
 
(12) Hirukawa I, et al. 小空洞に増大する菌球を胸腔鏡下部分肺切除で診断しえた肺アクチノマイコーシスの1例. 日呼吸誌. 2012 ; 1 : 464-9.
 
(13) Ryu JH, et al. Cystic and cavitary lung diseases : focal and diffuse. Mayo Clin Proc. 2003 ; 78 : 744-52.
PubMed
(14) Gadkowski LB, et al. Cavitary pulmonary disease. Clin Microbiol Rev. 2008 ; 21 : 305-33, table of contents.
PubMed
(15) Cosgrove GP, et al. Challenges in pulmonary fibrosis. 3 : Cystic lung disease. Thorax. 2007 ; 62 : 820-29.
PubMed
(16) Raoof S, et al. Cystic lung diseases : algorithmic approach. Chest. 2016 ; 150 : 945-65.
PubMed
(17) Ryu JH, et al. Diagnostic approach to the patient with diffuse lung disease. Mayo Clin Proc. 2002 ; 77 : 1221-7 ; quiz 7.
 
(18) Woodring JH, et al. Solitary cavities of the lung : diagnostic implications of cavity wall thickness. AJR Am J Roentgenol. 1980 ; 135 : 1269-71.
PubMed
P.178 掲載の参考文献
(1) Saraya T, et al. Spontaneous regression of Epstein-Barr virus-negative diffuse large B-cell lymphoma that presented with multiple pulmonary nodules. J Gen Fam Med. 2016 ; 17 : 244-8.
 
(1) McCool FD, et al. Dysfunction of the diaphragm. N Engl J Med. 2012 ; 366 : 932-42.
PubMed
(2) DiNino E, et al. Diaphragm ultrasound as a predictor of successful extubation from mechanical ventilation. Thorax. 2014 ; 69 : 423-7.
PubMed
(3) Cohn D, et al. Diaphragm thickening during inspiration. J Appl Physiol (1985). 1997 ; 83 : 291-6.
PubMed
(4) McCool F, et al. Diaphragm ultrasound in the intensive care unit. In : Jankowich M, et al. Ultrasound in the intensive care unit. New York : Humana Press ; 2015.
 
(5) Lichtenstein DA, et al. Relevance of lung ultrasound in the diagnosis of acute respiratory failure : the BLUE protocol. Chest. 2008 ; 134 : 117-25.
PubMed
(6) Mikura S, et al. Diaphragmatic dysfunction without paradoxical breathing : a case of nemaline myopathy. Pulm Res Respir Med Open J. 2016 ; SE : S22-4.
 
(7) Mikura S, et al. Diaphragm ultrasonography as a tool to assess the respiratory issues of a patient with amyotrophic lateral sclerosis (ALS). Pulm Res Respir Med Open J. 2016 ; SE : S20-1.
 
(8) Mikura S, et al. Diaphragm ultrasonography as a tool to assess paradoxical breathing in a patient with asthma attack. Pulm Res Respir Med Open J. 2016 ; SE : S14-6.
 

第5章 ANDSパールズ : 初級編 ( Basic )

P.183 掲載の参考文献
(1) 酸素療法の実際. In : 日本呼吸器学会肺生理専門委員会, 日本呼吸管理学会酸素療法ガイドライン作成委員会, 編. 酸素療法ガイドライン. 大阪 : メディカルレビュー社 ; 2006.
 
(2) 宮本顕二, 監. 酸素療法の手引き. 大阪 : 日本メディカルネクスト ; 2010.
 
(3) 酸素療法. URL ; www.covidien.co.jp/medical/academia/respiratory/oxygen
 
(4) 日本呼吸器学会NPPVガイドライン作成委員会, 編. NPPVガイドライン. 改訂第2版. 東京 : 南江堂 ; 2015.
 
P.196 掲載の参考文献
(1) West JB. 堀江孝至, 訳. ウエスト呼吸生理学入門 疾患編 第9章 酸素療法. 東京 : メディカル・サイエンス・インターナショナル ; 2009. p.181-95.
 
P.201 掲載の参考文献
(1) ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement : guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 ; 166 : 111-7.
PubMed
(2) Enright PL, et al. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998 ; 158 (5 Pt 1) : 1384-7.
 
(3) Enright PL, et al. Cardiovascular health study. The 6-min walk test : a quick measure of functional status in elderly adults. Chest. 2003 ; 123 : 387-93.
 
P.203 掲載の参考文献
(1) du Bois RM, et al. Six-minute-walk test in idiopathic pulmonary fibrosis : test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011 ; 183 : 1231-7.
PubMed
P.207 掲載の参考文献
(1) 日本呼吸器学会. パルスオキシメータハンドブック. 2014.
 
(2) http://www.konicaminolta.jp/healthcare/knowledge/details/principle.html
 
(3) https://www.jrs.or.jp/uploads/uploads/files/guidelines/pulse-oximeter_general.pdf
 
(4) Ioachimescu OC, et al. A middle-aged woman with chronic liver disease and shortness of breath. Cleve Clin J Med. 2006 ; 73 : 375-81.
PubMed
(5) Lange PA, et al. The hepatopulmonary syndrome. Ann Intern Med. 1995 ; 122 : 521-9.
PubMed
(6) Rodriguez-Roisin R, et al. Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med. 2008 ; 358 : 2378-87.
PubMed
(7) Kim YK, et al. Thoracic complications of liver cirrhosis : radiologic findings. Radiographics. 2009 ; 29 : 825-37.
PubMed
(8) 日本呼吸器学会肺生理専門委員会在宅呼吸ケア白書ワーキンググループ, 編. 在宅呼吸ケア白書. 日本呼吸器学会 ; 2010.
 
(9) Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease : a clinical trial. Ann Intern Med. 1980 ; 93 : 391-8.
 
(10) Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981 ; 1 : 681-6.
PubMed
(11) Neri M, et al. Long-term oxygen therapy in chronic respiratory failure : a Multicenter Italian Study on Oxygen Therapy Adherence (MISOTA). Respir Med. 2006 ; 100 : 795-806.
 
(12) ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement : guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 ; 166 : 111-7.
PubMed
(13) 日本産業・医療ガス協会. 公共輸送機関内における医療用酸素吸入について (平成24年9月改訂).
 
(14) Silverman D, et al. Medical issues associated with commercial flights. Lancet. 2009 ; 373 : 2067-77.
PubMed
(15) Muhm JM, et al. Effect of aircraft-cabin altitude on passenger discomfort. N Engl J Med. 2007 ; 357 : 18-27.
PubMed
(16) Ahmedzai S, et al. Managing passengers with stable respiratory disease planning air travel : British Thoracic Society recommendations. Thorax. 2011 ; 66 Suppl 1 : i1-30.
 
(17) Cramer D, et al. Assessment of oxygen supplementation during air travel. Thorax. 1996 ; 51 : 202-3.
PubMed
(18) Kelly PT, et al. Supplemental oxygen effect on hypoxemia at moderate altitude in patients with COPD. Aviat Space Environ Med. 2009 ; 80 : 815-9.
PubMed
P.222 掲載の参考文献
(1) Losel R, et al. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 2003 ; 4 : 46-56.
PubMed
(2) Jiang CL, et al. The novel strategy of glucocorticoid drug development via targeting nongenomic mechanisms. Steroids. 2015 ; 102 : 27-31.
PubMed
(3) http://www.igaku-shoin.co.jp/paperDetail.do?id=PA02973_09
 
P.226 掲載の参考文献
(1) Kelkar PS, et al. Cephalosporin allergy. N Engl J Med. 2001 ; 345 : 804-9.
PubMed
(2) Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1999 ; 74 : 730-4.
PubMed
(3) Farmakiotis D, et al. Images in clinical medicine. Metronidazole-associated encephalopathy. N Engl J Med. 2016 ; 374 : 1465.
PubMed
(4) Bhattacharyya S, et al. Antibiotic-associated encephalopathy. Neurology. 2016 ; 86 : 963-71.
PubMed
(5) Trotman RL, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005 ; 41 : 1159-66.
PubMed
(6) Kurai D, et al. Virus-induced exacerbations in asthma and COPD. Front Microbiol. 2013 ; 4 : 293.
PubMed
(7) Saraya T, et al. The molecular epidemiology of respiratory viruses associated with asthma attacks : a single-center observational study in Japan. Medicine (Baltimore). 2017 ; 96 : e8204.
PubMed
(8) Saraya T, et al. Epidemiology of virus-induced asthma exacerbations : with special reference to the role of human rhinovirus. Front Microbiol. 2014 ; 5 : 226.
 
(9) Saraya T, et al. Clinical significance of respiratory virus detection in patients with acute exacerbation of interstitial diseases. Respir Med. 2018 ; 136 : 88-92.
PubMed
(10) McGee S, et al. Use of corticosteroids in treating infectious diseases. Arch Intern Med. 2008 ; 168 : 1034-46.
PubMed
(11) Cushing H. The basophil adenoma of the pituitary body and their clinical manifestation. Johns Hopkins Med. 1932 ; 50 : 137.
 
(12) Miller ML. Glucocorticoid-induced myopathy. Up to Date 16.3, 2009.
 
(13) Lofberg E, et al. Effect of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur J Clin Invest. 2002 ; 32 : 345-53.
PubMed
(14) Anagnos A, et al. Endocrine myopathy. Neurol Clin. 1997 ; 15 : 673-96.
PubMed
(15) Qian T, et al. High-dose methylpredonisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord. 2005 ; 43 : 199-203.
 
(16) Guis S, et al. Drug-induced and toxic myopathies. Best Pract Res Clin Rheumatol. 2003 ; 17 : 877-907.
PubMed
(17) Ruff RL, et al. Endocrine myopathies. Neurol Clin. 1988 ; 6 : 575-92.
PubMed
(18) Rosa MRP, et al. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011 ; 78 : 41-4.
 
(19) Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006 ; 81 : 1361-7.
PubMed
(20) Bolanos SH, et al. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol. 2004 ; 92 : 500-5.
PubMed
(21) Drug-induced convulsions. Report from Boston Collaborative Drug Surveillance Program. Lancet. 1972 ; 2 : 677-9.
PubMed
(22) Lewis DA, et al. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord. 1983 ; 5 : 319-32.
 
(23) Salvatori R. Adrenal insufficiency. JAMA. 2005 ; 294 : 2481-8.
PubMed
(24) Dubovsky AN, et al. The neuropsychiatric complications of glucocorticoid use : steroid psychosis revisited. Psychosomatics. 2012 ; 53 : 103-15.
PubMed
(25) Buttgereit F, et al. Optimised glucocorticoid therapy : the sharpening of an old spear. Lancet. 2005 ; 365 : 801-3.
PubMed
(26) Schlaghecke R, et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med. 1992 ; 326 : 226-30.
 
(27) Sacre K, et al. Pituitary-adrenal function after prolonged glucocorticoid therapy for systemic inflammatory disorders : an observational study. J Clin Endocrinol Metab. 2013 ; 98 : 3199-205.
PubMed
(28) 柳瀬敏彦. 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日内分泌会誌. 2015 ; 91 (Suppl) : 1-78.
 
P.231 掲載の参考文献
(1) Kudoh S, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with lowdose erythromycin. Am J Respir Crit Care Med. 1998 ; 157 : 1829-32.
PubMed
(1) Tsujimoto N, et al. Tuberculous peritonitis incidentally diagnosed on FDG-PET/CT. Intern Med. 2013 ; 52 : 841-2.
PubMed
(2) Saraya T. Primary pleural lymphoma with dense pleural thickening. Pulm Res Respir Med Open J. 2015 ; 2 : 77-80.
 
(3) Saraya T, et al. A case of malignant peritoneal mesothelioma revealed with limitation of PET-CT in the diagnosis of thoracic metastasis. J Thorac Dis. 2013 ; 5 : E11-6.
PubMed
P.235 掲載の参考文献
(1) 川上憲司. 吸入シンチグラフィと肺内病変分布. 呼吸, 1995 ; 14 : 42-7.
Medical*Online
(2) 西間三馨, 他. β刺激薬の定量噴霧式吸入器の至適吸入方法の検討. 日小児アレルギー会誌. 1993 ; 5 : 6-16.
 
P.255 掲載の参考文献
(1) Kurai D, et al. Pathogen profiles and molecular epidemiology of respiratory viruses in Japanese inpatients with community-acquired pneumonia. Respir Investig. 2016 ; 54 : 255-63.
PubMed
(2) Saraya T, et al. Epidemiology of virus-induced asthma exacerbations : with special reference to the role of human rhinovirus. Front Microbiol. 2014 ; 5 : 226.
 
(3) Ryu JH, et al. Diagnostic approach to the patient with diffuse lung disease. Mayo Clin Proc. 2002 ; 77 : 1221-7 ; quiz 7.
 
(4) Saraya T, et al. Acute eosinophilic pneumonia masquerading as multiple pulmonary embolisms. BMJ Case Rep. 2016 ; 2016.
PubMed
(5) Saraya T, et al. Phantom tumour of the lung. BMJ Case Rep. 2013 ; 2013.
PubMed
(6) Saraya T. The History of Mycoplasma pneumoniae pneumonia. Front Microbiol. 2016 ; 7 : 364.
PubMed
(7) Saraya T, et al. Correlation between clinical features, high-resolution computed tomography findings, and a visual scoring system in patients with pneumonia due to Mycoplasma pneumoniae. Respir Investig. 2018 ; 56 : 320-5.
 
(8) Mansharamani NG, et al. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000 ; 118 : 712-20.
PubMed
(9) Lee SH, et al. Antibiotic susceptibility of bacterial strains isolated from patients with various infections. Lett Appl Microbiol. 2002 ; 34 : 215-21.
PubMed
(10) Tanaka Y, et al. Spontaneous resolution of Pneumocystis jirovecii pneumonia on high-resolution computed tomography in a patient with renal cell carcinoma. Am J Case Rep. 2014 ; 15 : 496-500.
 
(11) Brigden ML. Detection, education and management of the asplenic or hyposplenic patient. Am Fam Physician. 2001 ; 63 : 499-506, 8.
PubMed
(12) Potasman I, et al. The added value of peripheral blood cell morphology in the diagnosis and management of infectious diseases--part 2 : illustrative cases. Postgrad Med J. 2008 ; 84 : 586-9.
PubMed
(13) Nishizawa T, et al. Good syndrome occurred in a patient a prolonged time after thymectomy : a case report and literature review of cases in Japan. J Gen Fam Med. 2016 ; 17 : 238-43.
 
(14) Browne SK, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012 ; 367 : 725-34.
PubMed
(15) Kitami Y. Diagnostic criteria and classification of drug-induced hepatic injury. Kan-Tan-Sui. 1990 ; 21 : 379-41.
 
(16) Luque I, et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy. 2001 ; 56 : 611-8.
PubMed
(17) Matsuno O, et al. Drug-induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia. Tohoku J Exp Med. 2007 ; 212 : 49-53.
 
(18) Matsuno O. Drug-induced interstitial lung disease : mechanisms and best diagnostic approaches. Respir Res. 2012 ; 13 : 39.
PubMed
(19) Tamura M, et al. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. Oncologist. 2013 ; 18 : 454-9.
PubMed
(20) Ohnishi H, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003 ; 58 : 872-5.
PubMed
(21) Koide T, et al. A case of imatinib mesylate-induced pneumonitis based on the detection of epithelioid granulomas by video-assisted thoracoscopic surgery biopsy in a patient with chronic myeloid leukemia. Nihon Kokyuki Gakkai Zasshi. 2011 ; 49 : 465-71.
 
(22) Gotts JE, et al. Sepsis : pathophysiology and clinical management. BMJ. 2016 ; 353 : i1585.
PubMed
(23) Seymour CW, et al. Assessment of clinical criteria for sepsis : For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 ; 315 : 762-74.
PubMed
(24) Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 ; 315 : 801-10.
PubMed
P.261 掲載の参考文献
(1) Swartz MN. Bacterial meningitis : more involved than just the meninges. N Engl J Med. 1984 ; 311 : 912-4.
PubMed
(1) Jain S, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015 ; 373 : 415-27.
PubMed
(2) Honda K, et al. Multiple mycotic hepatic and splenic artery aneurysms in a patient with pneumococcal pneumonia : a case report with a review of the literature. Clin Case Rep. 2015 ; 3 : 891-6.
 
(2) Self WH, et al. Respiratory viral detection in children and adults : comparing asymptomatic controls and patients with community-acquired pneumonia. J Infect Dis. 2016 ; 213 : 584-91.
PubMed
(3) Kurai D, et al. Pathogen profiles and molecular epidemiology of respiratory viruses in Japanese inpatients with community-acquired pneumonia. Respir Investig. 2016 ; 54 : 255-63.
PubMed
(3) Carvalho AC, et al. Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. Clin Infect Dis. 2006 ; 42 : 893-5.
PubMed
(4) Saraya T, et al. Late-occurring paradoxical reaction masquerading as treatment failure for tuberculous adenitis. Intern Med. 2013 ; 52 : 2385-6.
PubMed
P.267 掲載の参考文献
(1) Dooley KE, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis. 2002 ; 34 : 1607-12.
PubMed
(2) Ginsburg AS, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 ; 37 : 1448-52.
PubMed
(3) Ginsburg AS, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med. 2003 ; 349 : 1977-8.
 
(4) Pablos-Mendez A, et al. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA. 1996 ; 276 : 1223-8.
PubMed
(5) Sherman LF, et al. Patient and health care system delays in the diagnosis and treatment of tuberculosis. Int J Tuberc Lung Dis. 1999 ; 3 : 1088-95.
PubMed
(6) Sharma SK, et al. Miliary tuberculosis : new insights into an old disease. Lancet Infect Dis. 2005 ; 5 : 415-30.
PubMed
(7) Itoh H. Imaging of pulmonary tuberculosis--valuable educational resources for the study of diagnostic imaging of the respiratory tract. Kekkaku. 2010 ; 85 : 869-79.
 
(8) 荒井他嘉司. 肺結核の外科治療と後遺症-その歴史的基礎知識と実際の対応. 診断と治療. 2007 ; 95 : 1987-96.
 
(9) 荒井他嘉司. 外科手術. 結核. 2011 ; 86 ; 627-31.
Medical*Online
(10) 四元秀殻, 他. 結核up to date 改訂第2版. 2011 ; 6 : 627-31.
 
(11) 日本結核病学会. 結核診療ガイドライン 改訂第3版. 東京 : 南江堂 ; 2015.
 
(12) 青木正和. 医師・看護職のための結核病学 3. 治療 (1) 結核化学療法の原則と実際. 平成22年改定版. 結核予防会 ; 2006.
 
(13) Saukkonen JJ, et al. An official ATS statement : hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006 ; 174 : 935-52.
PubMed
(14) 重藤えり子, 他. 抗結核薬使用中の肝障害への対応について. 平成18年11月. 結核. 2007 ; 82 : 115-8.
 
(15) 前川京子, 他. 【内科領域の薬剤性障害- 肝・肺を中心に】薬物性肝障害【総論】 薬物性肝障害の遺伝的素因 ゲノムバイオマーカーを用いた発症予測の可能性. 医学のあゆみ. 2014 ; 248 : 11-8.
 
P.277 掲載の参考文献
(1) Saraya T, et al. Breakthrough invasive Candida glabrata in patients on micafungin : a novel FKS gene conversion correlated with sequential elevation of MIC. J Clin Microbiol. 2014 ; 52 : 2709-12.
PubMed
(2) Rieder HL, et al. Epidemiology of tuberculosis in the United States. Epidemiol Rev. 1989 ; 11 : 79-98.
PubMed
(3) Hawkey CR, et al. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis. 2005 ; 40 : 1368-71.
PubMed
(4) Cheng VC, et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002 ; 21 : 803-9.
PubMed
(5) Geldmacher H, et al. Assessment of lymph node tuberculosis in northern Germany : a clinical review. Chest. 2002 ; 121 : 1177-82.
 
(6) Saraya T, et al. Late-occurring paradoxical reaction masquerading as treatment failure for tuberculous adenitis. Intern Med. 2013 ; 52 : 2385-6.
PubMed
(7) Short course chemotherapy for tuberculosis of lymph nodes : a controlled trial. British Thoracic Society Research Committee. Br Med J (Clin Res Ed). 1985 ; 290 : 1106-8.
PubMed
(8) Light RW. Update on tuberculous pleural effusion. Respirology. 2010 ; 15 : 451-8.
PubMed
(9) Tsujimoto N, et al. A simple method for differentiating complicated parapneumonic effusion/empyema from parapneumonic effusion using the split pleura sign and the amount of pleural effusion on Thoracic CT. PLoS One. 2015 ; 10 : e0130141.
PubMed
(10) Saraya T, et al. Hidden disease with pulmonary alveolar hemorrhage. J Gen Fam Med. 2016 ; 17 : 77-82.
 
(11) Marais S, et al. Tuberculous meningitis : a uniform case definition for use in clinical research. Lancet Infect Dis. 2010 ; 10 : 803-12.
PubMed
(12) McLain RF, et al. Spinal tuberculosis deserves a place on the radar screen. Cleve Clin J Med. 2004 ; 71 : 537-9, 43-9.
 
(13) Kurai D, et al. Pott's disease and cold abscesses. General Medicine. 2012 ; 13 : 110-2.
 
P.281 掲載の参考文献
(1) Tsuji S, et al. Community-acquired Pseudomonas aeruginosa pneumonia in previously healthy patients. JMM Case Reports. 2014. doi : 10.1099/jmmcr.0.000281
 
P.282 掲載の参考文献
(1) Saraya T, et al. Use of morphological evaluation using Ziehl-Neelsen stain for diagnosis of Mycobacterium kansasii. Gen Med. 2012 ; 13 : 53-4.
 
P.293 掲載の参考文献
(1) Demedts M, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005 ; 353 : 2229-42.
PubMed
(2) Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 ; 366 : 1968-77.
 
(3) Vancheri C, et al. Idiopathic pulmonary fibrosis : a disease with similarities and links to cancer biology. Eur Respir J. 2010 ; 35 : 496-504.
PubMed
(4) Takemura T, et al. Pathology of hypersensitivity pneumonitis. Curr Opin Pulm Med. 2008 ; 14 : 440-54.
PubMed
(5) Takemura T, et al. Pathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumonia. Histopathology. 2012 ; 61 : 1026-35.
PubMed
(6) du Bois R, et al. Challenges in pulmonary fibrosis x 5 : the NSIP/UIP debate. Thorax. 2007 ; 62 : 1008-12.
PubMed
(7) Ryerson CJ, et al. Predicting survival across chronic interstitial lung disease : the ILD-GAP model. Chest. 2014 ; 145 : 723-8.
PubMed
(8) King TE Jr, et al. Idiopathic pulmonary fibrosis. Lancet. 2011 ; 378 : 1949-61.
PubMed
(9) Kim DS, et al. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006 ; 3 : 285-92.
PubMed
(10) Saraya T, et al. Clinical significance of respiratory virus detection of interstitial lung diseases. Respir Med. 2018 ; 136 : 88-92.
PubMed
P.301 掲載の参考文献
(1) Hirata A, et al. Giant bulla formation in the lung because of a check-valve mechanism. Respir Investig. 2017 ; 55 : 63-8.
PubMed
(1) 山中晃. 肺病理アトラス-呼吸器疾患の立体的理解のために-. 東京 : 文光堂 ; 1990.
 
(2) 大畑正昭. 自然気胸. 東京 : 克誠堂出版 ; 1982. p.88-9.
 
(3) Noda M. Comparative studies on the operative findings and microscopic appearance of apontaneous pneumothorax. 日鏡外会誌. 2005 ; 10 : 189-95.
 
(4) Sahn SA, et al. Spontaneous pneumothorax. N Engl J Med. 2000 ; 342 : 868-74.
PubMed
(5) 中村治孝, 他. 自然気胸の治療方針. 呼吸. 2013 ; 32 : 307-16.
 
(6) 中澤健. 両側気胸. 呼吸. 2014 ; 33 ; 63-7.
Medical*Online
(7) Wait MA, et al. Changing clinical spectrum of spontaneous pneumothorax. Am J Surg. 1992 ; 164 : 528-31.
PubMed
(8) Tanaka F, et al. Secondary spontaneous pneumothorax. Ann Thorac Surg. 1993 ; 55 : 372-6.
PubMed
(9) Kong A. The Deep Sulcus Sign. Radiology. 2003 ; 228 : 415-6.
PubMed
(10) MacDuff A, et al. Management of spontaneous pneumothorax : British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 ; 65 (Suppl 2) : ii18-31.
 
(11) 山本昌樹. 自然気胸. 医学と薬学. 2013 ; 69 : 375-9.
Medical*Online
(12) 日本気胸・嚢胞性疾患学会. 自然気胸ガイドライン (案). 2009.
 
(13) Jackson RM, et al. Effects of hypoxia and reoxygenation on lung glutathione system. Am J Physiol. 1990 ; 259 : H518-24.
PubMed
(14) Sohara Y. Reexpansion pulmonary edema. Ann Thora Cardiovasc Surg. 2008 ; 14 : 205-9.
 
(15) Sakao Y, et al. Association of IL-8 and MCP-1 with the development of reexpansion pulmonary edema in rabbits. Ann Thorac Surg. 2001 ; 71 : 1825-32.
PubMed
(16) Pavlin J, et al. Unilateral pulmonary edema in rabbits after reexpansion of collapsed lung. J Appl Physiol : respiratory, environmental and exercise physiology. 1979 ; 46 : 31-5.
 
(17) Miller WC, et al. Experimental pulmonary edema following re-expansion of pneumothorax. Am Rev Tuberc. 1973 ; 108 : 654-6.
 
P.307 掲載の参考文献
(1) Tan EM, et al. Range of antinuclear antibodies in" healthy" individuals. Arthritis Rheum. 1997 ; 40 : 1601-11.
PubMed
P.310 掲載の参考文献
(1) Park JH, et al. Prognosis of fibrotic interstitial pneumonia : idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007 ; 175 : 705-11.
PubMed
(2) Kim EJ, et al. Rheumatoid arthritis-associated interstitial lung disease : the relevance of histopathologic and radiographic pattern. Chest. 2009 ; 136 : 1397-405.
PubMed
(3) Tansey D, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004 ; 44 : 585-96.
PubMed
(4) Takemura T. 非特異的間質性肺炎 (NSIP) : IPFとは独立した疾患か 病理組織像から. Jpn J Chest Dis. 2010 ; 69 : 20-8.
 
(5) Flaherty KR, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. 2001 ; 164 : 1722-7.
PubMed
(6) Hamaguchi Y, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies : heterogeneity within the syndrome. PLoS One. 2013 ; 8 : e60442.
PubMed
(7) Marie I, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012 ; 11 : 739-45.
PubMed
(8) Waseda Y, et al. Antisynthetase syndrome : pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases. Eur J Radiol. 2016 ; 85 : 1421-6.
PubMed
(9) Saraya T, et al. Massive tension pneumomediastinum. Intern Med. 2012 ; 51 : 677.
PubMed
P.318 掲載の参考文献
(1) Dweik RA, et al. An official ATS clinical practice guideline : interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011 ; 184 : 602-15.
PubMed
(2) 喘息予防管理ガイドライン2015作成委員会. 喘息予防管理ガイドライン 2015. 東京 : 協和企画 ; 2015.
 
(3) Smith AD, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005 ; 352 : 2163-73.
PubMed
(4) 清水大樹, 他. 判定の注意点-喫煙, アトピー素因, 鼻疾患-. 喘息. 2013 ; 26 : 129-33.
Medical*Online
(5) 滝澤始, 他. 微小粒子状物質 (PM2.5) をはじめとする大気汚染物質に高感受性を示すぜん息群の抽出とその増悪予防のための効率的な健康管理手法の確立に関する調査研究報告書 2014年度 (第10期). 東京 : 独立行政法人 環境再生保全機構 ; 2015.
 
(6) Takishima T, et al. Direct-writing recorder of the dose-response curves of the airway to methacholine. Clinical application. Chest. 1981 ; 80 : 600-6.
PubMed
(7) 福居嘉信, 他. 気管支喘息患者と若年成人無症候者におけるアストグラフ (R) 法による気道過敏性の検討. アレルギー. 2004 ; 53 : 565-74.
Medical*Online
(8) Corrao WM, et al. Chronic cough as the sole presenting manifestation of bronchial asthma. N Engl J Med. 1979 ; 300 : 633-7.
PubMed
(9) Matsumoto H, et al. Prognosis of cough variant asthma : a retrospective analysis. J Asthma. 2006 ; 43 : 131-5.
PubMed
(10) 日本呼吸器学会. 咳嗽に関するガイドライン 第2版. 2012.
 
(11) 清水大樹, 他. 咳診療における呼気一酸化窒素測定の有用性. 日呼吸会誌. 2011 ; 49 : 156-60.
Medical*Online
(12) An official ATS clinical practice guideline : Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011 ; 184 : 602-15.
PubMed
(13) Matsunaga K, et al. Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population. Allergol Int. 2010 ; 59 : 363-7.
PubMed
(14) Matsunaga K, et al. Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects. Allergol Int. 2011 ; 60 : 331-7.
PubMed
(15) Falsey AR, et al. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2010 ; 13 : 371-84.
 
(16) Jackson DJ, et al. The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol. 2010 ; 125 : 1178-87.
PubMed
(17) Saraya T, et al. The molecular epidemiology of respiratory viruses associated with asthma attacks : a single-center observational study in Japan. Medicine (Baltimore). 2017 ; 96 : e8204.
PubMed
(18) Contoli M, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006 ; 12 : 1023-6.
PubMed
P.324 掲載の参考文献
(1) Long-Term Oxygen Treatment Trial Research G. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med. 2016 ; 375 : 1617-27.
 
P.339 掲載の参考文献
(1) Mahler DA, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984 ; 85 : 751-8.
PubMed
(2) Jones PW, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992 ; 145 : 1321-7.
 
(3) Ware JE Jr, et al. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 ; 30 : 473-83.
PubMed
(4) 西村浩. 間質性肺炎の多面的評価-運動能力, 健康関連QoLおよび呼吸困難について (シンポジウム 間質性肺炎の呼吸ケア). 日呼吸ケアリハビリ会誌. 2010 ; 20 : 3-10.
 
(5) 日本呼吸器学会. COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン. 第4版. 2013.
 
(6) Calverley PM, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007 ; 356 : 775-89.
PubMed
(7) Suissa S, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013 ; 68 : 1029-36.
PubMed
(8) Crim C, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination : TORCH study results. Eur Respir J. 2009 ; 34 : 641-7.
 
(9) Miravitlles M, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014 : 1-16
 
(10) Magnussen H, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014 ; 371 : 1285-94.
PubMed
(11) Albert RK, et al. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med. 1980 ; 92 : 753-8
 
(12) Davies L, et al. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease : a prospective randomised controlled trial. Lancet. 1999. 7 ; 354 : 456-60.
PubMed
(13) Leuppi JD, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease : the REDUCE randomized clinical trial. JAMA. 2013. 5 ; 309 : 2223-31.
PubMed
(14) Czock D. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005 ; 44 : 61-98.
PubMed
(15) de Jong YP, et al. Oral or IV prednisolone in the treatment of COPD exacerbations : a randomized, controlled, double-blind study. Chest. 2007 ; 132 : 1741-7.
 
(16) Wilson R, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD : MAESTRAL results. Eur Respir J. 2012 ; 40 : 17-27
 
(17) Waschki B, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD : a prospective cohort study. Chest. 2011 ; 140 : 331-42.
PubMed
(18) Vaes AW, et al. Changes in physical activity and all-cause mortality in COPD. Eur Respir J. 2014 ; 44 : 1199-209.
PubMed
(19) Ries AL, et al. Pulmonary rehabilitation : Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest. 2007 ; 131 (5 Suppl) : 4S-42S.
 
(20) 塩谷隆信. 呼吸器リハビリテーション. アンチ・エイジング医学. 2012 ; 8 : 561-8.
Medical*Online
(21) 黒澤 一, 他. 呼吸器リハビリテーションの実際～ガイドラインとその用いかた～. Medicl Practice. 2006 ; 23 : 1057-62.
 
(22) 田中弥生. 栄養管理の実際. 日本呼吸ケア・リハビリテーション学会誌. 2015 ; 25 : 345-9.
 
(23) 青柴和徹, 他. 気管支喘息とCOPDの分岐点 : オーバーラップ症候群の考え方. 分子呼吸器病. 2013 ; 17 : 21-3.
Medical*Online
(24) 乾俊哉, 他. 喘息とCOPDの併存例 (ACOS) の診断と治療. 呼吸器内科. 2016 ; 29 : 510-6.
 
(25) Global Initiative for Asthma, Global Initiative for Chronic Obstructive Lung Disease. Asthma COPD and Asthma-COPD Overlap Syndrome (ACOS). http://goldcopd.org/asthma-copd-asthma-copd-overlap-syndrome/
 
(26) Miravitlles M, et al. Clinical phenotypes of COPD : identification, definition and implications for guidelines. Arch Bronconeumol. 2012 ; 48 : 86-98.
PubMed
(27) 足立満, 他. 本邦における高齢者喘息の現状と課題. アレルギー免疫. 2009 ; 16 : 248.
 
(28) 環境再生保全機構ホームページ. ぜん息などの情報館. http://www.erca.go.jp/yobou/zensoku/investigation/prevalence/01.html
 
(29) 喘息予防管理ガイドライン2015作成委員会. 喘息予防管理ガイドライン 2015. 東京 : 協和企画 ; 2015.
 
(30) Silva GE, et al. Asthma as a risk factor for COPD in a longitudinal study. Chest. 2004 ; 126 : 59-65.
 
(31) Hardin M, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011 ; 12 : 127.
PubMed
(32) Miravitlles M, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med. 2013 ; 107 : 1053-60.
PubMed
(33) de Marco R, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD) : prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One. 2013 ; 8 : e62985.
PubMed
(34) Menezes AM, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype COPD-asthma. Chest. 2014 ; 145 : 297-304.
PubMed
(35) 大林浩幸, 他. 難治性喘息とCOPDオーバーラップ症候群の診断と治療. アレルギーの臨床. 2013 ; 33 : 612-8.
 
(36) Iwamoto H, et al. Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur Respir J. 2014 ; 43 : 421-9.
PubMed
(37) 日本呼吸器学会. 喘息とCOPDのオーバーラップ (asthma and COPD overlap : ACO) 診断と治療の手引き 2018. 東京 : メディカルレビュー社 ; 2017.
 
P.344 掲載の参考文献
(1) Hori M, et al. Secondhand smoke exposure and risk of lung cancer in Japan : a systematic review and meta-analysis of epidemiologic studies. Jpn J Clin Oncol. 2016 ; 46 : 942-51.
PubMed
P.349 掲載の参考文献
(1) Wakai K, et al. Tobacco smoking and lung cancer risk : an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn J Clin Oncol. 2006 ; 36 : 309-24.
PubMed
(2) Katanoda K, et al. Population attributable fraction of mortality associated with tobacco smoking in Japan : a pooled analysis of three large-scale cohort studies. J Epidemiol. 2008 ; 18 : 251-64.
PubMed
(3) Sobue T, et al. Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women : the JPHC study. Int J Cancer. 2002. 99 : 245-51.
PubMed
(4) http://www.ies.or.jp/publicity_j/data/s19.pdf.
 
(5) Berrington de Gonzalez A, et al. Risk of cancer from diagnostic X-rays : estimates for the UK and 14 other countries. Lancet. 2004 ; 363 : 345-51.
PubMed
(6) 河北新報. https://www.kahoku.co.jp/special/spe1090/20180905_02.html
 
(7) 朝日新聞. https://www.ashahi.com/articles/ASLDF42SBLDFUBQU009.html
 
(8) Lynch KM, et al. Pulmonary asbestosis carcinoma of lung in asbestos-silicosis. Am J Cancer. 1935 ; 24.
 
(9) Merewether ERA. In : annual report of the chief inspector of factories for the year 1947. London : H.M. Stationary Office ; 1949.
 
(10) Rika T, et al. Comparison of analysis of annual medical check for silicosis patients and twice a year medical check for asbestos exposed retired workers. JJOMT. 2012 ; 60 : 137-9.
 
(11) Kannerstein M, et al. Pathology of carcinoma of the lung associated with asbestos exposure. Cancer. 1972 ; 30 : 14
PubMed
(12) Asbestos, asbestosis, and cancer : the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997 ; 23 : 311-6.
PubMed
(13) 廣島健三, 他. 石綿曝露の病理的評価. 肺癌. 2009 ; 49 : 48-57..
 
(14) Becklake MR. Asbestos-related diseases of the lung and other organs : Their epidemiology and implications for clinical practice. Am Rev Respir Dis. 1976 ; 114 : 187.
PubMed
(15) Stanton MF, et al. Relation of practice dimension to carcinogenicity in amphibole asbestos and other fibrous minerals. JNCI. 1981 ; 67 : 965.
 
(16) Apple JD, et al. Asbestos fiber mediate transformation of monkey cells by exogenous plasmid DNA. Proc Natl Acad Sci U S A. 1988 ; 85 : 7670.
 
(17) Richad D. Mortality from lung cancer in asbestos workers. Brit J industry Med. 1955 ; 12 : 81-6.
 
(18) McDonald JC. Mortality in the chrysotile asbestos mines and mills of Quebec. Arch Environ Health. 1971 ; 22 : 671.
 
P.353 掲載の参考文献
(1) Yankelevitz DF, et al. Does 2-year stability imply that pulmonary nodules are benign? Am J Roentgenol. 1997 ; 168 : 325-8.
 
(2) Revel MP, et al. Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules. Am J Roentgenol. 2006 ; 187 : 135-42.
 
(3) Mikita K, et al. Growth rate of lung cancer recognized as small solid nodule on initial CT findings. Eur J Radiol. 2012 ; 81 : e548-53.
PubMed
P.361 掲載の参考文献
(1) Seo SI, et al. Comparison of recurrence patterns between < 5 years and > 5 years after curative operations in colorectal cancer patients. J Surg Oncol. 2013 ; 108 : 9-13.
PubMed
(2) Cho YB, et al. Clinical and pathologic evaluation of patients with recurrence of colorectal cancer five or more years after curative resection. Dis Colon Rectum. 2007 ; 50 : 1204-10.
PubMed
(3) Watanabe K, et al. Incidence and predictive factors for pulmonary metastases after curative resection of colon cancer. Ann Surg Oncol. 2013 ; 20 : 1374-80.
PubMed
(4) Watanabe K, et al. Predictive factors for pulmonary metastases after curative of rectal cancer without preoperative chemoradiotherapy. Dis Colon Rectum. 2011 ; 54 : 989-98.
PubMed
(5) 田中規文, 他. 乳癌晩期再発例の検討. 日臨外会誌. 1988 : 49 : 2248-2251.
 
(6) 萩谷朗子, 他. 乳癌切除21年を経ての肺転移巣の1切除例. 日臨外会誌. 2001 ; 62 : 1425-8.
 
(7) 鈴木恵理, 他. 乳癌術後35年目に癌性胸膜炎で再発した1例. 気管支学. 2004 ; 26 : 383-7.
Medical*Online
(8) 石綱一央, 他, 乳癌術後25年以上を経て再発した2例. 日臨外会誌. 2011 ; 72 : 863-8.
 
(9) 中村幸生, 他. 乳癌術後25年目に肺転移再発を来した1例. 日呼外会誌. 2008 ; 22 : 890-3.
 
(10) 山上良, 他, 乳癌手術後16年目に孤立性肺転移を生じた1例. 臨外. 2013 ; 68 : 1505-9.
 
(11) Son HS, et al. Factors affecting the time to recurrence after radical nephrectomy for localized renal cell carcinoma. Korean J Urol. 2013 : 4 : 744-9.
PubMed
(12) Matsumura Y, et al, et al. Early and late recurrence after intentional limited resection for cT1aN0M0, non-small cell lung cnacer : from a multi-institutional, retrospective analysis in Japan. Interact Cardiovasc Thorac Surg. 2016 ; 23 : 444-9.
 
(13) Maeda R, et al. Late recurrence of non-small cell lung cancer more than 5 years after complete resection incidence and clinical implication in patient follow-up. Chest. 2010 ; 138 : 145-50.
PubMed
(14) Thomford NR, et al. The surgical treatment of metastatic tumor inthe lungs. J Thorac Cardiovasc Surg. 1965 ; 49 : 357-63.
 
(15) Mirels H, et al. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relate Res. 1989 ; 249 : 256-64.
 
(16) Taneichi H, et al. Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spines. Spine. 1997 ; 22 : 239-45.
PubMed
(17) Fisher CG, et al. A novel classification system for spinal instability in neoplastic disease : an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine. 2010 ; 35 : E1221-9.
 
(18) 松尾圭祐, 他. 気道ステント留置術のガイドラインの必要性について. 気管支学. 2007 ; 29 : 26-9.
Medical*Online
(19) Chamberlain MC, et al. Leptomeningeal metastasis : a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol. 2014 ; 16 : 1176-85.
 
(20) Le Rhun E, et al. Carcinomatous meningitis : Leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013 ; 4 : 265-88.
 
(21) Glantz MJ, et al. Cerebrospinal fluid cytology in patients with cancer : minimizing false-negative results. Cancer. 1998 ; 82 : 733-9.
PubMed
(22) Kang SJ, et al. Diagnostic value of cerebrospinal fluid level of carcinoembryonic antigen in patients with leptomeningeal carcinomatous metastasis. J Clin Neurol. 2010 ; 6 : 33-7.
PubMed
(23) 須藤淳子, 他. 肺癌における癌性髄膜炎の検討. 日呼吸会誌. 2006 ; 44 : 795-9.
Medical*Online
(24) Chamberlain MC, et al. Carcinomatous meningitis. Arch Neurol. 1997 ; 54 : 16-7.
PubMed
(25) Umemura S, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer : Okayama Lung Cancer Study Group. Lung Cancer. 2012 ; 77 : 134-39.
 
(26) Lee E, et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol. 2013 ; 8 : 1069-74.
PubMed
(27) Kawamura T, et al. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs. Cancer Chemother Pharmacol. 2015 ; 75 : 1261-6.
PubMed
(28) Gong L, et al. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations. Lung Cancer. 2015 ; 89 : 268-73.
PubMed

第6章 ANDSパールズ : 中級編 ( Standard )

P.370 掲載の参考文献
(1) Pabst R, et al. Lymphocyte dynamics : caution in interpreting BAL numbers. Thorax. 1997 ; 52 : 1078-80.
PubMed
(2) Pabst R, et al. Lymphocytes in the lung : an often neglected cell. Numbers, characterization and compartmentalization. Anat Embryol (Berl). 1995 ; 192 : 293-9.
PubMed
(3) Kohlmeier JE, et al. Memory T cell recruitment to the lung airways. Curr Opin Immunol. 2006 ; 18 : 357-62.
 
(4) Wardlaw AJ, et al. Mechanisms of T cell migration to the lung. Clin Exp Allergy. 2005 ; 35 : 4-7.
 
P.379 掲載の参考文献
(1) Altiner A, et al. Sputum colour for diagnosis of a bacterial infection in patients with acute cough. Scand J Prim Health Care. 2009 ; 27 : 70-3.
PubMed
(2) Johnson AL, et al. Sputum color : potential implications for clinical practice. Respir Care. 2008 ; 53 : 450-4.
PubMed
(3) Miravitlles M, et al. Sputum colour and bacteria in chronic bronchitis exacerbations : a pooled analysis. Eur Respir J. 2012 ; 39 : 1354-60.
PubMed
(4) Daniels JM, et al. Sputum colour reported by patients is not a reliable marker of the presence of bacteria in acute exacerbations of chronic obstructive pulmonary disease.Clin Microbiol Infect. 2010 ; 16 : 583-8.
 
(5) Robert A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000 ; 117 : 1638-45.
 
(6) Allegra L, et al. Sputum color as a marker of aute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med. 2005 ; 99 : 742-7.
 
(7) Meyer KC, et al. An Official American Thoracic Society Clinical Practice Guideline : The Clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012 ; 185 : 1004-14.
PubMed
(8) 日本呼吸器学会びまん性肺疾患学術部会, 厚生労働省難治性疾患克服研究事業びまん性肺疾患調査研究班, 編. 気管支肺胞洗浄 [BAL] 法の手引き 改訂第2版. 東京 : 克誠堂出版 ; 2008. p.3-108.
 
(9) The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis. 1990 ; 141 : S169-202.
 
(10) 近藤光子. 気管支肺胞洗浄 (BAL). 気管支学. 2005 ; 27 : 401-5.
Medical*Online
(11) Costabel U, et al. Sensitivity and specificity of BAL findings in sarcoidosis. Sarcoidosis. 1992 ; 9 (Suppl 1) : 211-4.
 
(12) Dominguez J, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest. 2001 ; 119 ; 243-9.
PubMed
(13) 佐藤長人, 他. 肺炎球菌尿中抗原迅速検出キットの有用性と抗原反応強度・持続期間の検討. 日呼吸会誌. 2004 ; 42 ; 247-52.
Medical*Online
(14) 中西雅樹, 他. 肺炎球菌尿中抗原陽性を呈したStreptococcus oralis, Granulicatella adiacens誤嚥性肺炎・菌血症の1例. 日呼吸会誌. 2014 ; 3 ; 133-6.
 
(15) 吉田佳成子, 他. 肺炎球菌尿中抗原検出キットを用いた尿中抗原陽性持続期間についての検討. 日呼吸会誌. 2003 ; 41 ; 521-5.
Medical*Online
(16) 村上日奈子. 尿中レジオネラ抗原検査. モダンメディア. 2004 ; 50 ; 86-91.
 
(17) Shimada T, et al. Systematic review and metaanalysis : urinary antigen tests for legionellosis. Chest. 2009 ; 136 ; 1576-85.
PubMed
(18) 舘田一博. レジオネラ感染症の最新の診断と治療. 埼玉医大誌. 2003 ; 30 ; 91-8.
 
(19) 中根茂喜, 他. アンチバイオグラムを作成・活用する. 薬局. 2012 ; 63 : 62-7.
 
(20) 神田善伸, 監訳. 好中球減少を呈する癌患者に対する抗微生物薬の使用に関する実践的臨床ガイドライン : 米国感染症学会による2010年改訂版. CID. 2011 ; 52 : 11-8.
 
(21) Birch DF, et al. Urinary erythrocyte morphology in the diagnosis of glomerular hematuria. Clin Nephrol. 1983 ; 20 : 78-84.
PubMed
(22) Crop MJ, et al. Diagnostic value of urinary dysmorphic erythrocytes in clinical practice. Nephron Clin Pract. 2010 ; 115 : c203-12.
PubMed
(23) 血尿診断ガイドライン編集委員会, 他編. 血尿診断ガイドライン. 東京 : ライフサイエンス出版 ; 2013.
 
(24) 喘息予防管理ガイドライン2015作成委員会. 喘息予防管理ガイドライン 2015. 東京 : 協和企画 ; 2015.
 
(25) Katayama H, et al. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990 ; 175 : 621-8.
PubMed
(26) 鳴海善文, 他. 非イオン性ヨード造影剤およびガドリニウム造影剤の重症副作用および死亡例の頻度調査. 日本医放会誌. 2005 ; 65 : 300-1.
 
(27) 早川克己, 他. 造影剤添付文書の「原則禁忌」について考える. 臨床画像. 2007 ; 23 : 358-65.
 
(28) American College of Radiology : Manual on Contrast Media, Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf
 
(29) Grobner T, et al. Gadolium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006 ; 21 : 1104-8.
 
(30) 日本医学放射線学会, 日本腎臓学会. 腎障害患者におけるガドリウム造影剤使用に関するガイドライン. 2009.
 
(31) 厚生労働省. 医療品医療機器等安全性情報. No 285. 2011/11.
 
(32) 腎障害患者におけるヨード造影剤使用に関するガイドライン. 2012.
 
P.383 掲載の参考文献
(1) Golde DW, et al. Occult pulmonary haemorrhage in leukaemia. Br Med J. 1975 ; 2 : 166-8.
PubMed
(2) Epstein CE, et al. Time course of hemosiderin production by alveolar macrophages in a murine model. Chest. 2001 ; 120 : 2013-20.
 
(3) Sherman JM, et al. Time course of hemosiderin production and clearance by human pulmonary macrophages. Chest. 1984 ; 86 : 409-11.
PubMed
(4) Maldonado F, et al. Haemosiderin-laden macrophages in the bronchoalveolar lavage fluid of patients with diffuse alveolar damage. Eur Respir J. 2009 ; 33 : 1361-6.
PubMed
P.391 掲載の参考文献
(1) Gefter WB. The spectrum of pulmonary aspergillosis. J Thorac Imaging. 1992 ; 7 : 56-74.
PubMed
(2) Segal BH, et al. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. 2006 ; 173 : 707-17.
PubMed
(3) Cuenca-Estrella M, et al. Detection and investigation of invasive mould disease. J Antimicrob Chemother. 2011 ; 66 (Suppl 1) : i15-24.
 
(4) Oda M, et al. Calcium oxalate crystal deposition in a patient with Aspergilloma due to Aspergillus niger. J Thorac Dis. 2013 ; 5 : E174-8.
 
(5) Yoshida K. The correlation between tissue injury and calcium oxalate crystal production in rat's lung with experimental Aspergillus niger infection. Kansenshogaku Zasshi. 1998 ; 72 : 621-30.
 
(6) 深在性真菌症ガイドライン作成委員会. 深在性真菌症の診断・治療ガイドライン 2014. 東京 : 協和企画 ; 2014.
 
(7) 藤内智, 他. 慢性壊死性肺アスペルギルス症臨床診断におけるガラクトマンナン抗原およびβ-Dグルカン値の検討. 日本呼吸器学会誌. 2009 ; 47 : 7-11.
 
(8) 吉田耕一郎. アスペルギルス感染症の血清診断法と (1-3) -β-D-グルカン測定法の進歩. 真菌誌, 2006 ; 47 : 135-42.
 
(9) Kono Y, et al. The utility of galactmannan antigen in the bronchial washing and serum for diagnosing pulumonry aspergillosis. Respiratory Medicine. 2013 ; 107 : 1094-100.
PubMed
(10) 安藤陽一郎, 他. 血清アスペルギルス沈降抗体検査症例の臨床的検討. 日呼吸会誌. 2012 ; 1 : 3-8.
 
(11) Sada M, et al. Invasive tracheobronchial aspergillosis in a patient with systemic lupus erythematosus-dermatomyositis overlap syndrome. Intern Med. 2013 ; 52 : 2149-53.
 
(12) McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol. 2014 ; 12 : 252-62.
PubMed
(13) Martin-Loeches I, et al. Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med. 2017 ; 43 : 48-58.
PubMed
(14) Rosenberg M, et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977 ; 86 : 405-14.
PubMed
(15) Greenberger PA, et al. Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. J Allergy Clin Immunol. 1988 ; 81 : 646-50.
PubMed
(16) Vlahakis NE, et al. Diagnosis and treatment of allergic bronchopulmonary aspergillosis. Mayo Clin Proc. 2001 ; 76 : 930-8.
PubMed
(17) Stevens DA, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000 ; 342 : 756-62.
PubMed
P.400 掲載の参考文献
(1) Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015 ; 372 : 1832-43.
PubMed
(2) Fleming RE, et al. Hepcidin : a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci U S A. 2001 ; 98 : 8160-2.
PubMed
(3) Andrews NC. Anemia of inflammation : the cytokine-hepcidin link. J Clin Invest. 2004 ; 113 : 1251-3.
 
(4) Weiss G, et al. Anemia of chronic disease. N Engl J Med. 2005 ; 352 : 1011-23.
PubMed
(5) 睡眠呼吸障害研究会, 編. 成人の睡眠時無呼吸症候群診断と治療のためのガイドライン. 東京 : メディカルレビュー社 ; 2005.
 
(6) Sleep-related breathing disorders in adults : recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999 ; 22 : 667-89.
PubMed
(7) Collop NA, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2007 ; 3 : 737-47.
PubMed
(8) American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien : American Academy of Sleeo Medicine ; 2014.
 
(9) Peppard PE, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000, 284 : 3015-21.
PubMed
(10) Marshall NS, et al. Is sleep apnea an independent risk factor for prevalent and incident diabetes in the Busselton Health Study? J Clin Sleep Med. 2009 ; 15:15-20.
PubMed
(11) Yaggi HK, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005 ; 353 : 2034-41.
PubMed
(12) Reichmuth KJ, et al. Association of sleep apnea and type II diabetes : a population-based study. Am J Respir Crit Care Med. 2005 : 172 : 1590-5.
PubMed
(13) Martinez-Garcia MA, et al. Cardiovascular mortality in obstructive sleep apnea in the elderly : role of long-term continuous positive airway pressure treatment : a prospective observational study. Am J Respir Crit Care Med. 2012 ; 186 : 909-16.
PubMed
(14) Martinez-Garcia MA, et al. Continuous positive airway pressure treatment reduces mortality in patients with ischemic stroke and obstructive sleep apnea : a 5-year follow-up study. Am J Respir Crit Care Med. 2009 ; 180 : 36-41.
PubMed
(15) Grobner T, et al. Gadolium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006 ; 21 : 1104-8.
 
(16) Mermel LA, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection : 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009 ; 49 : 1-45.
 
(17) Siegman-Igra Y, et al. Diagnosis of vascular catheter-related bloodstream infection : a meta-analysis. J Clin Microbiol. 1997 ; 35 : 928-36.
PubMed
(18) Blot F, et al. Diagnosis of catheter-related bacteraemia : a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet. 1999 ; 354 : 1071-7.
PubMed
(19) Stryjewski ME, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007 ; 44 : 190-6.
 
(20) Wisplinghoff H, et al. Nosocomial bloodstream infection in US hospitals:analysis of 24,179 cases from aprospective nationwide surveillance study. Clin infect Dis. 2004 ; 39 : 309-17.
 
(21) Clinical Practice Guidelines for the Giagnosis and Management of Intravascular Catheter-Related Infection ; 2009 Update by Infectious Diseases of America.
 
(22) 宇野俊介, 他. 深在性カンジダ症の診断と治療. 臨床検査. 2014 ; 58 : 75-80.
 
(23) Saraya T, et al. Breakthrough invasive Candida glabrata in patients on micafungin : a novel FKS gene conversion correlated with sequential elevation of MIC. J Clin Microbiol. 2014 ; 52 : 2709-12.
PubMed
(24) Saraya T, et al. Case of candidemia with Candida glabrata with confirmation of the acquisition of micafungin sensitivity due to new mutation of FKS gene mutation. Kansenshogaku Zasshi, 2014 ; 88 (3 Suppl 9-10) : 1-5.
 
(25) 掛屋弘, 他. 呼吸器真菌症診療の進歩 3. カンジダ症. 日胸臨. 2014 ; 73 : 1029-39.
 
(26) Imaizumi T, et al. Analysis of the background facters leading to catheter-related Candida bloodstream infectin in our hospital-effort to prevent complications by ICT-. Jpn J Infect Prevent Control. 2012 ; 27 : 8-12.
 
P.409 掲載の参考文献
(1) International Commission on Radiological Protection (ICRP). Publication 84. Pregnancy and medical radiation. Ann ICRP. 2000 ; 30.
 
(2) 日本産科婦人科学会, 日本産婦人科医会. 産婦人科診療ガイドライン-産科編. 2017. p.67.
 
(3) 野崎太希. 胎児・小児期の放射線被曝. 京府医大誌. 2011 ; 120 : 931-40.
 
(4) National Council on Radiation Protection and Measurements. Medical radiation exposure of pregnant and potentially pregnant women. NCRP Report. 1977 ; No. 54.
 
(5) ACOG Committee on Obstetric Practice. ACOG Committee Opinion, Number 299, September 2004 (replaces No.158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol. 2004 ; 299 : 647-51.
PubMed
(6) Hall EJ. Scientific view of low-level radiation risks. Radiographics. 1991 ; 11 : 509-18.
PubMed
(7) Schull WJ. Brain damage among individuals exposed prenatally to ionizing radiation : a 1993 review. Stem Cells. 1997 ; 15 : 129-33.
PubMed
(8) Yamazaki J, et al. Perinatal loss and neurological abnormalities among children of the atomic bomb. Nagasaki and Hiroshima revisited, 1949 to 1989. JAMA. 1990 ; 264 : 605-9.
PubMed
(9) Australian Drug Evaluation Committee (ADEC). Australian categorization system for prescribing medicines in pregnancy. http://www.tga.gov.au/prescribing-medicines-pregnancy-database
 
(10) Kozer E, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies : a meta-analysis. Am J Obstet Gynecol. 2002 ; 187 : 1623-30.
PubMed
(11) Nezvalova-Henriksen K, et al. Effects of codeine on pregnancy outcome : results from a large population-based cohort study. Eur J Clin Pharmacol. 2011 ; 67 : 1253-61.
PubMed
(12) Creanga AA, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol. 2010 ; 115 : 717-26.
PubMed
(13) Norgard B, et al. Therapeutic drug use in women with Crohn's disease and birth outcomes : a Danish nationwide cohort study. Am J Gastroenterol. 2007 ; 102 : 1406-13.
PubMed
(14) Bar Oz B, et al. Pregnancy outcome after cyclosporine therapy during pregnancy : a meta-analysis. Transplantation. 2001 ; 71 : 1051-5.
PubMed
(15) Ostensen M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006 ; 8 : 209.
PubMed
(16) 永川明香, 他. 小児科医が知っておくべき妊娠中の注意事項 妊産婦と薬剤. 小児科診療. 2013 ; 76 : 1967-73.
 
(17) Kwon HL, et al. Asthma prevalence among pregnant and child-bearingaged women in the United States : estimates from national health surveys. Ann Epidemiol. 2003 ; 13 : 317-24.
 
(18) Kallen B, et al. Congenital ma1formations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol. 1999 ; 93 : 392-5.
PubMed
(19) Park-Wyllie L, et al. Birth defects after maternal exposure to corticosteroids : prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000 ; 62 : 385-92.
PubMed
(20) Martel MJ, et al. Use of short-acting beta2-agonists during pregnancy and the risk of pregnancy-induced hypertension. J Allergy Clin Immunol. 2007 ; 119 : 576-82.
PubMed
(21) Cossette B, et al. Impact of maternal use of asthma controller therapy on perinatal outcomes. Thorax. 2013 ; 68 : 724-30.
 
(22) Sarkar M, et al. Montelukast use during pregnancy : a multicentre, prospective, comparative study of infant outcomes. Eur J Clin Pharmacol. 2009 ; 65 : 1259-64.
PubMed
(23) Namazy J, et al. The Xolair Pregnancy Registry (EXPECT) : the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015 ; 135 : 407-12.
PubMed
(24) Sugarman J, et al. Tuberculosis in pregnancy : an estimate of the global burden of disease. Lancet Glob Health. 2014 ; 2 : e710-6.
PubMed
(25) 平成29年結核登録者情報調査年報集計結果について. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000175095_00001.html
 
(26) Mathad JS, et al. Tuberculosis in pregnant and postpartum women : epidemiology, management, and research gaps. Clin Infect Dis. 2012, 55 : 1532-49.
PubMed
(27) 日本結核病学会, 編. 結核診療ガイドライン. 改訂第3版. 東京 : 南江堂 ; 2015. p.77-96.
 
(28) Snider DE, et al. Treatment of tuberculosis during pregnancy. Am Rev Res Dis. 1980 ; 134 : 65-79.
 
(29) World Health Organization. Guidelines for treatment of tuberculosis. 4th ed. 2010. p.97.
 
(30) Snider DE Jr, et al. Should women taking antituberculosis drugs breast-feed? Arch Intern Med. 1984 ; 144 : 589-90.
PubMed
(31) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000 ; 161 : S221-47.
PubMed
P.416 掲載の参考文献
(1) Temel JS, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 ; 363 : 733-42.
PubMed
(2) 日本緩和医療学会. 緩和医療ガイドライン作成委員会. がん疼痛の薬物療法に関するガイドライン 2014年版. 東京 : 金原出版 : 2014.
 
(3) Bruera E, et al. Subcutaneous morphine for dyspnea in cancer patients. Ann Int Med. 1993 ; 119 : 9066-907.
 
(4) Clemens KE, et al. Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage. 2007 ; 33 : 473-81.
PubMed
(5) Navigante AH, et al. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage. 2006 ; 31 : 38-47.
 

第7章 ANDSパールズ : 上級編 ( Advanced )

P.429 掲載の参考文献
(1) Ando M, et al. Difference in the phenotypes of bronchoalveolar lavage lymphocytes in patients with summer-type hypersensitivity pneumonitis, farmer's lung, ventilation pneumonitis, and bird fancier's lung. J Allergy Clin Immunol. 1991 ; 87 : 1002-9.
PubMed
(2) 仲谷善彰, 他. 多数の抗原とエンドトキシンの関与が疑われた加湿器肺の1 例. 日胸疾会誌. 1997 ; 35 : 1232-7.
 
P.432 掲載の参考文献
(1) Cunha BA, et al. Legionnaires' disease. Lancet. 2016 ; 387 : 376-85.
PubMed
(2) Stout JE, et al. Legionellosis. N Engl J Med. 1997 ; 337 : 682-7.
PubMed
(3) Shah A, et al. Legionnaires' disease and acute renal failure : case report and review. Clin Infect Dis. 1992 ; 14 : 204-7.
PubMed
(4) Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int. 1996 ; 49 : 314-26.
PubMed
(5) Shimura C, et al. Pathological evidence of rhabdomyolysis-induced acute tubulointerstitial nephritis accompanying Legionella pneumophila pneumonia. J Clin Pathol. 2008 ; 61 : 1062-3.
PubMed
P.433 掲載の参考文献
(1) Nakajima A, et al. Familial summer-type hypersensitivity pneumonitis in Japan : two case reports and review of the literature. BMC Res Notes. 2013 ; 6 : 371.
PubMed
(2) Inase N, et al. Chronic summer-type hypersensitivity pneumonitis : clinical similarities to idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2007 ; 24 : 141-7.
PubMed
(3) Ohtani Y, et al. Chronic hypersensitivity pneumonitis. 日本胸部臨床. 2010 ; 69 : 29-37.
 
(4) Okamoto T, et al. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Respir Med. 2015 ; 109 : 1576-81.
PubMed
(5) Silva CI, et al. Chronic hypersensitivity pneumonitis : differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology. 2008 ; 246 : 288-97.
PubMed
(6) Ohtani Y, et al. Clinical features of recurrent and insidious chronic bird fancier's lung. Ann Allergy Asthma Immunol. 2003 ; 90 : 604-10.
PubMed
(7) Matsubara M, et al. Cytological evaluation of atypical lymphocytes in bronchoalveolar lavage fluid of hypersensitivity pneumonitis. Jpn Soc Clin Cytol. 2000 ; 39 : 408-9.
 
(8) Okamoto T, et al. Nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig. 2013 ; 51 : 191-9.
PubMed
(9) Inase N, et al. Chronic summer-type hypersensitivity pneumonitis : clinical similarities to idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2007 ; 24 : 141-7.
PubMed
(10) Takemura T, et al. Pathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumonia. Histopathology. 2012 ; 61 : 1026-35.
PubMed
(11) Wada S, et al. Chronic hypersensitivity pneumonitis caused by Trichosporon antigen inhalation and diagnosed with video-assisted thoracoscopic surgery. 日胸臨. 2016 ; 75 : 551-6.
 
(12) Jain S, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015 ; 372 : 835-45.
PubMed
(13) Jain S, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015 ; 373 : 415-27.
PubMed
(14) Self WH, et al. Respiratory viral detection in children and adults : comparing asymptomatic controls and patients with community-acquired pneumonia. J Infect Dis. 2016 ; 213 : 584-91.
PubMed
(15) Kurai D, et al. Pathogen profiles and molecular epidemiology of respiratory viruses in Japanese inpatients with community-acquired pneumonia. Respir Investig. 2016 ; 54 : 255-63.
PubMed
(16) Jennings LC, et al. Incidence and characteristics of viral community acquired pneumonia in adults. Thorax. 2008 ; 63 : 42-8.
PubMed
(17) Huijskens EG, et al. The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community-acquired pneumonia. J Med Microbiol. 2014 ; 63 : 441-52.
PubMed
(18) Choi SH, et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med. 2012 ; 186 : 325-32.
PubMed
P.442 掲載の参考文献
(1) Raghu G, et al. An official ATS/ERS/JRS/ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 ; 183 : 788-824.
PubMed
(2) Collard HR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007 ; 176 : 636-43.
PubMed
(3) Song JW, et al. Acute exacerbation of idiopathic pulmonary fibrosis : incidence, risk factors and outcome. Eur Respir J. 2011 ; 37 : 356-63.
PubMed
(4) Oda K, et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2014 ; 15 : 109.
PubMed
(5) Wootton SC, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 ; 183 : 1698-702.
PubMed
(6) Santos GC, et al. Immunohistochemical detection of virus through its nuclear cytopathic effect in idiopathic interstitial pneumonia other than acute exacerbation. Braz J Med Biol Res, 2013 ; 46 : 985-92.
PubMed
(7) Ushiki A, et al. Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia. Respir Investig. 2014 ; 52 : 65-70.
PubMed
(8) Moore BB, et al. Viruses in idiopathic pulmonary fibrosis. etiology and exacerbation. Ann Am Thorac Soc. 2015. Suppl 2 : S186-92.
 
(9) Saraya T, et al. Clinical significance of respiratory virus detection in patients with acute exacerbation of interstitial lung diseases. Respir Med. 2018 ; 136 : 88-92.
PubMed
(10) Kurai D, et al. Virus-induced exacerbations in asthma and COPD. Front Microbiol. 2013 ; 4 : 293.
PubMed
(11) Raghu G, et al. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004 ; 91 (Suppl 2) : S3-10.
 
(12) Sato T, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg. 2015 ; 149 : 64-70.
PubMed
(13) Sato T, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014 ; 147 : 1604-11.
PubMed
(14) Sato T, et al. A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg. 2015 ; 63 : 164-172.
 
(15) Saraya T, et al. Cellular non-specific interstitial pneumonia masquerading as congestive heart failure. BMJ Case Rep. 2013 ; 2013.
PubMed
(16) Hartman TE, et al. Nonspecific interstitial pneumonia : variable appearance at high-resolution chest CT. Radiology. 2000 ; 217 : 701-5.
PubMed
(17) Cordier JF. Organising pneumonia. Thorax. 2000 ; 55 : 318-28.
PubMed
(18) Drakopanagiotakis F, et al. Organizing pneumonia. Am J Med Sci. 2008 ; 335 : 34-9.
PubMed
(19) Lohr RH, et al. Organizing pneumonia. Features and prognosis of cryptogenic, secondary, and focal variants. Arch Intern Med. 1997 ; 157 : 1323-9.
PubMed
(20) Maldonado F, et al. Focal organizing pneumonia on surgical lung biopsy : causes, clinicoradiologic features, and outcomes. Chest. 2007 ; 132 : 1579-83.
PubMed
(21) Lazor R, et al. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d'Etudes et de Recherche sur les Maladles "Orphelines" Pulmonaires (GERM "O" P). Am J Respir Crit Care Med. 2000 ; 162 (2 Pt 1) : 571-7.
 
(22) Nakatsu M, et al. Large coalescent parenchymal nodules in pulmonary sarcoidosis : "sarcoid galaxy" sign. AJR Am J Roentgenol. 2002 ; 178 : 1389-93.
PubMed
(23) Aikins A, et al. Galaxy sign. J Thorac Imaging. 2012 ; 27 : W164.
PubMed
(24) Heo JN, et al. Pulmonary tuberculosis : another disease showing clusters of small nodules. AJR Am J Roentgenol. 2005 ; 184 : 639-42.
PubMed
(25) Koide T, et al. Clinical significance of the "galaxy sign" in a Japanese single-center cohort. Sarcoidosis Vasc Diffuse. Lung Dis. 2016 ; 33 : 247-52.
 
P.453 掲載の参考文献
(1) Bouros D, et al. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study. Am J Respir Crit Care Med. 1999 ; 159 : 37-42.
PubMed
(2) Tuncozgur B, et al. Intrapleural urokinase in the management of parapneumonic empyema : a randomised controlled trial. Int J Clin Pract. 2001 ; 55 : 658-60.
PubMed
(3) Diacon AH, et al. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med. 2004 ; 170 : 49-53.
PubMed
(4) Maskell NA, et al. U. K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005 ; 352 : 865-74.
 
(5) Rahman NM, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011 ; 365 : 518-26.
PubMed
(6) Tokuda Y, et al. Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions : a meta-analysis. Chest. 2006 ; 129 : 783-90.
PubMed
(7) Janda S, et al. Intrapleural fibrinolytic therapy for treatment of adult parapneumonic effusions and empyemas : a systematic review and meta-analysis. Chest. 2012 ; 142 : 401-11.
PubMed
(8) Iuchi K, et al. Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer. 1987 ; 60 : 1771-5.
PubMed
(9) Fukayama M, et al. Epstein-Barr virus in pyothorax-associated pleural lymphoma. Am J Pathol. 1993 ; 143 : 1044-9.
PubMed
(10) Sasajima Y, et al. High expression of the Epstein-Barr virus latent protein EB nuclear antigen-2 on pyothorax-associated lymphomas. Am J Pathol. 1993 ; 143 : 1280-5.
PubMed
(11) Nakatsuka S, et al. Pyothorax-associated lymphoma : a review of 106 cases. J Clin Oncol. 2002 ; 20 : 4255-60.
 
(12) 斎藤一浩. ガリウムシンチグラフィーが有用であった慢性膿胸に発生した悪性リンパ腫の2例. 臨床放射線. 1998 ; 43 : 855-8.
 
(13) 白山裕士. ガリウムシンチグラフィーが有用であった膿胸関連リンパ腫の2例. 核医学. 2001 ; 38 : 223-8.
 
(14) Colice GL, et al, Littenberg B, et al. Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline. Chest. 2000 ; 118 : 1158-71.
PubMed
(15) Light RW. Clinical practice. Pleural effusion. N Engl J Med. 2002 ; 346 : 1971-7.
PubMed
(16) Mikasa K, et al. The JAID/JSC Guideline to Clinical Management of Infectious Diseases (Respiratory infections). Kansenshogaku Zasshi. 2014 ; 88 : 1-109.
PubMed
(17) Kraus GJ. The split pleura sign. Radiology. 2007 ; 243 : 297-8.
PubMed
(18) Tsujimoto N, et al. A simple method for differentiating complicated parapneumonic effusion/empyema from parapneumonic effusion using the split pleura sign and the amount of pleural effusion on thoracic CT. PLOS ONE. 2015 ; 10 : e0130141.
PubMed
(19) Udaya BS, et al. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion : analysis of 414 Cases. Mayo Clin Proc. 1985 ; 60 : 158-64.
 
(20) BTS Pleural Disease Guideline 2010 Thorax. 2010 ; 65 (Suppl 2) : ii4-ii17.
 
(21) Niwa Y, et al. Carcinomatous and tuberculous pleural effusions. Comparison of tumor markers. Chest. 1985 ; 87 : 351-5.
PubMed
(22) 多田敦彦, 他. 肺癌癌性胸膜炎と結核性胸膜炎における胸水中腫瘍マーカー. 日呼吸会誌. 2002 ; 40 : 106-12.
Medical*Online
(23) Salama G, et al. Evaluation of pleural CYFR 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusion. Br J Cancer. 1998 ; 77 : 472-6.
 
(24) Clive AO, et al. Predicting survival in malignant pleural effusion : development and validation of the LENT prognostic score. Thorax. 2014 ; 69 : 1098-104.
PubMed
P.477 掲載の参考文献
(1) 日本肝臓学会 肝炎診療ガイドライン作成委員会. B型肝炎治療ガイドライン (第3版). 2017.
 
(1) Auperin A, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999 ; 341 : 476-84.
 
(2) Umemura T, et al. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Inter Med. 2006 ; 45 : 747-8.
 
(2) Arriagada R, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995 ; 87 : 183-90.
PubMed
(3) Gregor A, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer : results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer. 1997 ; 33 : 1752-8.
PubMed
(4) Meert AP, et al. Prophylactic cranial irradiation in small cell lung cancer : a systematic review of the literature with meta-analysis. BMC Cancer. 2001 ; 1 : 5.
PubMed
(5) Le Pechoux C, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01) : a randomised clinical trial. Lancet Oncol. 2009 ; 10 : 467-74.
PubMed
(6) Wolfson AH, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212 : impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiate Oncol Biol Phys. 2011 ; 81 : 77-84.
 
(7) Slotman B, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. EORTC Radiation Oncology Group and Lung Cancer Group. N Engl J Med. 2007 ; 357 : 664-72.
 
(8) Seto T, et al. Prophylactic cranial irradiation has a detrimental effect on the overall survival of patients with extensive disease small cell lung cancer : Results of a Japanese randomized phase III trial. J Clin Oncol. 2012 ; 32 : suppl. Abstract 7503.
 
(9) 日本肺癌学会. EBM手法による肺癌診療ガイドライン 2015. https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3
 
(10) Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis-the role of homeostasis-. Carcinogenesis. 2000 ; 21 : 857-64.
PubMed
(11) Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science. 2002 ; 297 : 63-4.
PubMed
(12) Kohno T, et al. RET fusion gene : translation to personalized lung cancer therapy. Cancer Sci. 2013 ; 104 : 1396-400.
PubMed
(13) 先端医療開発センター. http://epoc.ncc.go.jp/scrum/lc_scrum/
 
(14) Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 ; 361 : 947-57.
 
(15) Fukuoka M, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 ; 29 : 2866-74.
PubMed
(16) Maemondo M, et al. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med. 2010 ; 362 : 2380-8.
 
(17) Mitsudomi T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial. Lancet Oncol. 2010 ; 11 : 121-8.
PubMed
(18) Rosell R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC) : a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 ; 13 : 239-46.
PubMed
(19) Zhou C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL. CTONG-0802) : a multicentre, open-label, randomised phase 3 study. Lancet Oncol. 2011 ; 12 : 735-42.
PubMed
(20) Sequist LV, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 ; 31 : 3327-34.
 
(21) Wu YL, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) : an open-label, randomised phase 3 trial. Lancet Oncol. 2014 ; 15 : 213-22.
PubMed
(22) Inoue A, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatinpaclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013 ; 24 : 54-9.
PubMed
(23) Mitsudomi T, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol. 2012 ; 30 : (suppl ; abstr 7521).
 
(24) Zhou C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015 ; 26 : 1877-83.
PubMed
(25) Yang JC, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6) : analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 ; 16 : 141-51.
PubMed
(26) Kato T, et al. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations : subgroup analysis of LUX-Lung 3. Cancer Sci. 2015 ; 106 : 1202-11.
PubMed
(27) Sequist LV, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 ; 3 : 75ra26.
PubMed
(28) Cortot AB, et al. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur Respir Rev. 2014 ; 23 : 356-66.
PubMed
(29) Gandara DR, et al. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer : approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 ; 15 : 1-6.
PubMed
(30) Chaft JE, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib : implications for clinical trial design. Clin Cancer Res. 2011 ; 17 : 6298-303.
PubMed
(31) Oxnard GR, et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 2011 ; 17 : 5530-7.
PubMed
(32) Soria JC, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS) : a phase 3 randomised trial. Lancet Oncol. 2015 ; 16 : 990-8.
PubMed
(33) Janne PA, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 : 372 : 1689-99.
PubMed
(34) Suda K, et al. Small cell lung cancer transformation and T790M mutation : complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Sci Rep. 2015 ; 5 : 14447.
PubMed
(35) J Clin Oncol 34, 2016 (suppl ; abstr 9001)
 
(36) Oxnard GR, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016 ; 34 : 3375-82.
PubMed
(37) Finkelstein DM, et al. Long-term survivors in metastatic non-small-cell lung cancer : an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1986 ; 4 : 702-9.
 
(38) Lilenbaum RC, et al. Prevalence of poor performance status in lung cancer patients : implications for research. J Thorac Oncol. 2008 ; 3 : 125-9.
 
(39) Zukin M, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013 ; 31 : 2849-53.
PubMed
(40) Lee SM, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL) : a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012 ; 13 : 1161-70.
PubMed
(41) Inoue A, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009 ; 27 : 1394-400.
PubMed
(42) Okuma Y, et al. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status. Anti Res. 2013 ; 33 : 5057-64.
 
(43) Kudoh S, et al. Interstitial lung disease in Japanese patients with lung cancer : a cohort and nested case-control study. Am J Respir Crit Care Med. 2008 ; 177 : 1348-57.
PubMed
(44) Ando M, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006 ; 24 : 2549-56.
PubMed
(45) Shaw AT, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 ; 368 : 2385-94.
PubMed
(46) Solomon BJ, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 ; 371 : 2167-77.
PubMed
(47) Gadgeel SM, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG) : results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014 ; 15 : 1119-28.
PubMed
(48) Ardizzoni A, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer : an individual patient data meta-analysis. J Natl Cancer Inst. 2007 ; 99 : 847-57.
PubMed
(49) Okamoto H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer : JCOG 9702. Br J Cancer. 2007 : 97 : 162-9.
PubMed
(50) Pignon JP, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992 ; 327 : 1618-24.
PubMed
(51) Ueki N, et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol. 2015 ; 10 : 116-25.
PubMed
(52) Bahig H, et al. Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease. Pract Radiat Oncol. 2016 ; 6 : 367-74.
PubMed
(53) Ozawa Y, et al. Impact of preexisting interstitial lung disease on acute, extensive radiation pneumonitis : retrospective analysis of patients with lung cancer. PLoS One. 2015 ; 10 : e0140437.
PubMed
(54) Takeda A, et al. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors. Int J Radiat Oncol Biol Phys. 2010 ; 77 : 685-90.
PubMed
(55) Yamaguchi S, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease : the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013 ; 82 : 260-5.
PubMed
(56) Kenmotsu H, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thoracic Oncol. 2011 ; 6 : 1242-6.
PubMed
(57) Kudoh S, et al. Interstitial lung disease in Japanese patients with lung cancer : a cohort and nested case-control study. Am J Respir Crit Care Med. 2008 ; 177 : 1348-57.
PubMed
(58) 弦間昭彦. 特発性間質性肺炎合併肺癌に対する化学療法の現況と治療関連急性増悪に関する実態調査. びまん性肺疾患に関する調査研究班, 平成21年度研究報告書. 2010. p.105-7.
 
(59) Minegishi Y, et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Inter Med. 2009 ; 48 : 665-72.
 
(60) Minegishi Y, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2011 ; 71 : 70-4.
PubMed
(61) Minegishi Y, et al. The feasibility study of carboplatin plus etoposide for advanced small-cell lung cancer withidiopathic interstitial pneumonias. J Thorac Oncol. 2011 ; 6 : 801-7.
 
(62) Kudoh S, et al. Japan Thoracic Radiology Group. Interstitial lung disease in Japanese patients with lung cancer : a cohort and nested case-control study. Am J Respir Crit Care Med. 2008 ; 177 : 1348-57.
PubMed
(63) Satouchi M. Use of ALK inhibitors in the clinical setting-patient selection and side effect management- . JJLC. 2015 ; 55 : 956-61.
 
(64) アレセンサ(R) カプセル市販直後調査における副作用集計結果報告 : 2014年9月5日～2015年3月4日.
 
(65) 日本肺癌学会. 抗PD-1抗体薬ニボルマブ (オプジーボ(R)) についてのお願い (追加). http://www.haigan.gr.jp/modules/important/index.php?content_id=58
 
(66) Nishino M, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med. 2015 ; 373 : 288-90.
PubMed
(67) Hanna N, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with nons-mall-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 ; 22 : 1589-97.
 
(68) Okamoto I, et al. Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naive patients with advanced nonsquamous non-small-cell lung cancer. Invest New Drugs. 2013 ; 31 : 1275-82.
PubMed
(69) Patel JD, et al. PointBreak : a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 ; 31 : 4349-57.
PubMed
(70) Totani Y, et al. Phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2009 ; 64 : 1181-85.
PubMed
(71) Okamoto I, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer : results of a west Japan oncology group study. J Clin Oncol. 2010 ; 28 : 5240-6.
 
(72) J Clin Oncol. 2012 ; 30 : (suppl ; abstr 7515).
 
(73) Crino L, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer : a phase II trial. J Clin Oncol. 1999 ; 17 : 2081-5.
PubMed
(74) Treat JA, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2010 ; 21 : 540-7.
 
(75) J Clin Oncol. 2012 ; 30 : (suppl ; abstr 7592).
 
(76) Frasci G, et al. J Clin Oncol. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. 2000 ; 18 : 2529-36.
PubMed
(77) Takeda K, et al. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer : a West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs. 2007 ; 25 : 377-83.
 
(78) Masuda N, et al. CPT-11 : a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992 ; 10 : 1225-9.
PubMed
(79) Kinoshita A, et al. Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. Br J Cancer. 2006 ; 94 : 1267-71.
PubMed
(80) Zatloukal P, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010 ; 21 : 1810-6.
PubMed
(81) Okamoto H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer : JCOG 9702. Br J Cancer. 2007 ; 97 : 162-9.
PubMed
(82) Mitsudomi T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial. Lancet Oncol. 2010 ; 11 : 121-8.
PubMed
(83) Goto K, et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer. 2013 ; 82 : 109-14.
PubMed
(84) Wolf S, et al. Chemotherapy-induced peripheral neuropathy : prevention and treatment strategies. Eur J Cancer. 2008 : 44 : 1507-15.
PubMed
(85) Kolb NA, et al. The Association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 2016 ; 73 : 860-6.
PubMed
(86) Arakawa K. Chemotherapy-induced peripheral neuropathy : clinical symptoms, managements and mechanism. Jpn J Pharm Palliat Care Sci. 2011 ; 4 : 1-13.
 
(87) Socinski MA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer : final results of a phase III trial. J Clin Oncol. 2012 ; 30 : 2055-62.
PubMed
(88) Ohno T, et al. Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer. Anticancer Res. 2014 ; 34 : 4213-6.
PubMed
(89) Cella D, et al. Measuring the side effects of taxane therapy in oncology : the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer. 2003 ; 98 : 822-31.
PubMed
(90) Groover T, et al. Intrathoracic changes following roentgen treatment of breast carcinoma. AJR Am J Roentgenol. 1923 ; 10 : 471-6.
 
(91) Arbetter KR, et al. Radiation-induced pneumonitis in the "nonirradiated" lung. Mayo Clin Proc. 1999 ; 74 : 27-36.
PubMed
(92) Prakash UB. Radiation-induced injury in the "nonirradiated" lung. Eur Respir J. 1999 ; 13 : 715-7.
PubMed
P.491 掲載の参考文献
(1) 羽白高, 他. びまん性肺疾患に関する調査研究班. A. 特発性間質性肺炎 II. 臨床像に関する研究 イムノキャップ特異IgGキットを用いたハト・オウム・セキセイインコIgG抗体値のカットオフ値の検討. びまん性肺疾患に関する調査研究班 平成21年度研究報告書. 2010. p.187-9.
 
(2) Inase N, et al. Measurement of bird specific antibody in bird-related hypersensitivity pneumonitis. Nihon Kokyuki Gakkai Zasshi. 2011 ; 49 : 717-22.
PubMed
(3) Cottin V, et al. Combined pulmonary fibrosis and emphysema : a distinct underrecognised entity. Eur Respir J. 2005 ; 26 : 586-93.
PubMed
(4) Marten K, et al. Non-specific interstitial pneumonia in cigarette smokers : a CT study. Eur Radiol. 2009 ; 19 : 1679-85.
 
(5) Katzenstein AL, et al. Clinically occult interstitial fibrosis in smokers : classification and significance of a surprisingly common finding in lobectomy specimens. Hum Pathol. 2010 ; 41 : 316-25.
PubMed
(6) Cottin V. The impact of emphysema in pulmonary fibrosis. Eur Respir Rev. 2013 ; 22 : 153-7.
PubMed
(7) Cottin V, et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum. 2011 ; 63 : 295-304.
PubMed
(8) Kawabata Y, et al. Smoking-related changes in the background lung of specimens resected for lung cancer : a semiquantitative study with correlation to postoperative course. Histopathology. 2008 ; 53 : 707-14.
PubMed
(9) Jankowich MD, et al. Combined pulmonary fibrosis and emphysema syndrome : a review. Chest. 2012 ; 141 : 222-31.
PubMed
(10) Amitani R, et al. Idiopathic pulmonary upper lobe fibrosis (IPUF). Kokyu. 1992 ; 11 : 693-9.
 
(11) Frankel SK, et al. Idiopathic pleuroparenchymal fibroelastosis : description of a novel clinicopathologic entity. Chest. 2004 ; 126 : 2007-13.
PubMed
(12) von der Thusen JH, et al. Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Patol. 2011 ; 24 : 1633-9.
 
(13) Camus P, et al. Pleuroparenchymal fibroelastosis : one more walk in the wild side of drugs? Eur Respir J. 2014 ; 44 : 289-96.
PubMed
(14) Beynat-Mouterde C, et al. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. Eur Respir J. 2014 ; 44 : 523-7.
PubMed
(15) Watanabe K. Secondary pleuroparenchymal fibroelastosis : Mycobacterium avium complex, ulcerative colitis, after esophagus cancer irradiation, after lung transplantation. JSSOG. 2013 ; 33 : 57-60.
 
(16) Piciucchi S, et al. High resolution CT and histological findings in idiopathic pleuroparenchymal fibroelastosis : features and differential diagnosis. Respir Res. 2011 ; 12 : 111.
PubMed
(17) von der Thusen JH. Pleuroparenchymal fibroelastosis : its pathological characteristics. Curr Repir Med Rev. 2013 ; 9 : 238-47.
 
(18) Harada T, et al. The thoracic cage becomes flattended in the progression of pleuroparenchymal fibroelastosis. Eur Respir Rev. 2014 ; 23 : 263-6.
 
(19) Enomoto N, et al. Quantitative analysis of lung elastic fibers in idiopathic pleuroparenchymal fibroelastosis : comparison of clinical, radiological, and pathological findings with those of idiopathic pulmonary fibrosis. BMC Pulm Med. 2014 ; 14 : 91.
PubMed
(20) Kusagaya H, et al. Idiopathic pleuroparenchymal fibroelastosis : consideration of a clinicopathological entity in a series of Japanese patients. BMC Pulm Med. 2012 ; 12 ; 72.
 
(22) Watanabe K. Pleuroparenchymal fibroelastosis : its clinical characteristics. Curr Respir Med Rev. 2013 ; 9 : 237-99.
 
(22) Maraia A, et al. Rare idiopathic interstitial pneumonias : LIP and PPFE and rare histological patterns of interstitial pneumonias : AFOP and BPIP. Respiology. 2015 ; 10 : 1-15.
 
(23) Chen F, et al. Lung transplantation for pleuroparenchymal fibroelastosis after chemotherapy. Ann Thorac Surg. 2014 ; 98 : 115-7.
 
(24) Eisenstadt HB. Asbestos Pleurisy. Dis Chest. 1964 ; 46 : 78-81.
PubMed
(25) Epler GR, et al. Prevalence and incidence of benign asbestos pleural effusion in a working population. JAMA. 1982 ; 247 : 617-22.
 
(26) Hillerdal G, et al. Benign asbestos pleural effusion : 73 exudates in 60 patients. Eur J Respir Dis. 1987 ; 71 : 113-21.
PubMed
(27) O'Reilly KM, et al. Asbestos-related lung disease. Am Fam Physician. 2007 ; 75 : 683-8.
PubMed
(28) https://jsite.mhlw.go.jp/tokyo-roudoukyoku/var/rev0/0145/6299/201772182516.pdf
 
(29) 環境再生保全機構. 石綿と健康被害. https://www.erca.go.jp/asbestos/what/kenkouhigai/pdf/panphlet.pdf
 
P.503 掲載の参考文献
(1) スティーヴン・ジョンソン, 著. 矢野真千子, 訳. 感染地図-歴史を変えた未知の病原体-. 東京 : 河出書房新社 ; 2007.
 
P.504 掲載の参考文献
(1) Tsushima K, et al. Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome. J Clin Apher. 2002 ; 17 : 97-102.
PubMed
(1) 竹村公太郎. 日本文明の謎を解く. 東京 : 清流出版 ; 2003. 第8章.
 
(2) Seo Y, et al. Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Inter Med. 2006 ; 45 : 1033-8.
 
(3) Abe S, et al. Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia : a pilot study. Blood Purif. 2010 ; 29 : 321-6.
PubMed
(4) Abe S, et al. Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation : a multicenter retrospective analysis. Intern Med. 2012 ; 51 : 1487-91.
PubMed
(5) Izumi S, et al. Potential benefits of early direct hemoperfusion with polymyxin B-immobilized fiber columns for patients with rapidly progressive interstitial pneumonia. Am J Respir Crit Care Med. 2014 ; 189 : A1436.
 
(6) Kono M, et al. Evaluation of different perfusion durations in direct hemoperfusion with polymyxin B-immobilized fiber column therapy for acute exacerbation of interstitial pneumonias. Blood Purif. 2011 ; 32 : 75-81.
PubMed
(7) Bernard GR, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987 ; 317 : 1565-70.
PubMed
(8) Steinberg KP, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006 ; 354 : 1671-84.
PubMed
(9) Meduri GU, et al. Methylprednisolone infusion in early severe ARDS : results of a randomized controlled trial. Chest. 2007 ; 131 : 954-63.
PubMed
(10) Tang BM, et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome : a systematic review and meta-analysis. Crit Care Med. 2009 ; 37 : 1594-603.
PubMed
(11) Meduri GU, et al. Steroid treatment in ARDS : a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med. 2008 ; 34 : 61-9.
PubMed
(12) Agarwal R, et al. Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis. Respirology. 2007 ; 12 : 585-90.
PubMed
(13) 日本血液製剤ホームページ. http://www.ketsukyo.or.jp/
 
(14) Perez EE, et al. Update on the use of immunoglobulin in human disease : a review of evidence. J Allergy Clin Immunol. 2016 ; S0091-6749 : 31141-1.
 
(15) Alejandria MM, et al. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013 ; 9 : CD001090.
PubMed
(16) Soares MO, et al. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock) : incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess. 2012 ; 16 : 1-186.
PubMed
(17) Arellano-Orden E, et al. Small particle-size talc is associated with poor outcome and increased inflammation in thoracoscopic pleurodesis. Respiration. 2013 ; 86 : 201-9.
PubMed
(18) Kasahara K, et al. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer. Anticancer Res. 2006 ; 26 : 1495-9.
PubMed
(19) Yoshida K, et al. Randomized phase II trial of three intrapleural therapy regimens for management of malignant pleural effusion in previously untreated non-small cell lung cancer : JCOG 9515. Lung Cancer. 2007 ; 58 : 362-8.
PubMed
(20) Blanco I, et al. Pleurodesis with the patient's own blood : the initial results in 14 cases : Arch Bronconeumol. 1996 ; 32 : 230-6.
 
(21) Andreetti C, et al. Pleurodesis with an autologous blood patch to prevent persistent air leaks after lobectomy. J Thorac Cardiovasc Surg. 2007 ; 133 : 759-62.
PubMed
(22) Rafinski RA. Uber die Behandlungsmoglichkeit, des Spontanpneumothorax von kindern mit einer zeitweilingen Plobiereng des sogenannten Drainagebronchus. Prax Pneumol. 1968 ; 19 : 736-46.
 
(23) 渡辺洋一. EWS(R) を用いた気管支充填術. EWSハンドブック. 2013
 
(24) 渡辺洋一. 気管支充填術. 気管支学. 2005 ; 27 : 475-8.
Medical*Online
(25) Ueyama M, et al. Three cases of intractable pneumothorax treated successfully with bronchial occlusion using Endobronchial Watanabe Spigots and coagulation factor XIII. JJSR. 2010 ; 32 : 224-8.
 

書評

最近チェックした商品履歴

Loading...